[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 84 of about 84
1. Yang WC, Huang YC, Tsai MH, Chiu CH, Jaing TH: Salmonella septic arthritis involving multiple joints in a girl with acute lymphoblastic leukemia at diagnosis. Pediatr Neonatol; 2009 Feb;50(1):33-5
MedlinePlus Health Information. consumer health - Salmonella Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salmonella septic arthritis involving multiple joints in a girl with acute lymphoblastic leukemia at diagnosis.
  • Septic arthritis due to Salmonella has been reported frequently, but multiple joint involvements have rarely been reported in children.
  • A 3-year-old girl presented with Salmonella arthritis involving multiple joints.
  • Laboratory investigations revealed pancytopenia inconsistent with diagnosis of juvenile rheumatoid arthritis or septic arthritis.
  • Bone marrow examination 2 weeks later confirmed the diagnosis of acute lymphoblastic leukemia (ALL).
  • This case illustrates that a delay in the diagnosis may occur when there is an apparent infection focus without classic features of leukemia.
  • Multiple joints involvement of septic arthritis associated with pancytopenia should highlight the possibility of underlying hematologic disorders.
  • [MeSH-major] Arthritis, Infectious / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Salmonella Infections / etiology


2. O'Rielly DD, Rahman P: Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmgenomics Pers Med; 2010;3:15-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.
  • Rheumatoid arthritis (RA) is a chronic heterogeneous autoimmune disorder of unknown etiology resulting in inflammation in the synovium, cartilage, and bone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1978 Apr 20;298(16):869-71 [147420.001]
  • [Cites] Rheum Dis Clin North Am. 1992 Nov;18(4):741-59 [1280845.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):844-9 [1818543.001]
  • [Cites] Arthritis Rheum. 1987 Nov;30(11):1205-13 [2446635.001]
  • [Cites] Clin Genet. 1989 Sep;36(3):178-82 [2676268.001]
  • [Cites] Ann Intern Med. 1989 Oct 15;111(8):641-9 [2802419.001]
  • [Cites] Cell. 1986 Aug 29;46(5):705-16 [3091258.001]
  • [Cites] Am J Hum Genet. 1988 Oct;43(4):414-21 [3177384.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] J Rheumatol. 1995 Jun;22(6):1032-6 [7674226.001]
  • [Cites] J Clin Invest. 1993 Sep;92(3):1387-93 [7690781.001]
  • [Cites] Pharmacogenetics. 1994 Feb;4(1):39-42 [8004131.001]
  • [Cites] Am J Gastroenterol. 1993 Aug;88(8):1198-205 [8338087.001]
  • [Cites] Gut. 1995 Nov;37(5):674-8 [8549944.001]
  • [Cites] J Immunol. 1996 Mar 1;156(5):1937-41 [8596047.001]
  • [Cites] J Inherit Metab Dis. 1996;19(5):589-94 [8892013.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] Clin Exp Immunol. 1998 Sep;113(3):401-6 [9737669.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2856-62 [9763570.001]
  • [Cites] Crit Rev Immunol. 1998;18(5):389-418 [9784967.001]
  • [Cites] Ann Intern Med. 1998 Nov 1;129(9):716-8 [9841604.001]
  • [Cites] Arthritis Rheum. 1998 Dec;41(12):2196-204 [9870876.001]
  • [Cites] Arthritis Rheum. 1999 Jun;42(6):1071-9 [10366098.001]
  • [Cites] Scand J Gastroenterol Suppl. 1999;230:111-5 [10499471.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Arthritis Rheum. 2000 Jan;43(1):30-7 [10643697.001]
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001158 [10796420.001]
  • [Cites] J Immunol. 2001 Mar 15;166(6):4177-84 [11238669.001]
  • [Cites] Gut. 2001 May;48(5):591-2 [11302950.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Apr;57(1):51-4 [11372592.001]
  • [Cites] Lancet. 2001 Sep 15;358(9285):903-11 [11567728.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Nov;15(11):1699-708 [11683683.001]
  • [Cites] Arthritis Rheum. 2001 Nov;44(11):2525-30 [11710708.001]
  • [Cites] Exp Hematol. 2002 Mar;30(3):237-44 [11882361.001]
  • [Cites] Rheumatology (Oxford). 2002 Feb;41(2):180-3 [11886967.001]
  • [Cites] Gut. 2002 Apr;50(4):485-9 [11889067.001]
  • [Cites] Hum Immunol. 2002 Jan;63(1):76-81 [11916172.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):183-90 [11927833.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):921-8 [11953968.001]
  • [Cites] Semin Arthritis Rheum. 2002 Jun;31(6):355-60 [12077707.001]
  • [Cites] Pharmacogenetics. 2002 Aug;12(6):429-36 [12172211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12281-6 [12213961.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4388-98 [12370372.001]
  • [Cites] Ann Rheum Dis. 2003 Jan;62(1):4-9 [12480661.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):593-600 [12684695.001]
  • [Cites] Arthritis Rheum. 2003 May;48(5):1398-407 [12746913.001]
  • [Cites] Ann Rheum Dis. 2003 Jun;62(6):526-9 [12759288.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Rheumatology (Oxford). 2004 Feb;43(2):156-63 [12923290.001]
  • [Cites] Clin Rheumatol. 2003 Sep;22(3):221-4 [14505215.001]
  • [Cites] Drug Saf. 2003;26(13):983-9 [14583072.001]
  • [Cites] Genes Immun. 2004 May;5(3):151-7 [14749714.001]
  • [Cites] Arthritis Rheum. 2004 Feb;50(2):400-12 [14872482.001]
  • [Cites] Pharm Res. 2004 Feb;21(2):324-9 [15032315.001]
  • [Cites] Arthritis Res Ther. 2004;6(2):R142-50 [15059278.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2167-79 [15152062.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):330-7 [15208781.001]
  • [Cites] Ther Drug Monit. 2004 Apr;26(2):186-91 [15228163.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2113-21 [15248208.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):1052-60 [15334086.001]
  • [Cites] Ann Rheum Dis. 2005 Apr;64(4):575-81 [15345504.001]
  • [Cites] Ann Rheum Dis. 2004 Oct;63(10):1227-31 [15361376.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2750-6 [15457442.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2766-74 [15457444.001]
  • [Cites] Arthritis Rheum. 2004 Oct;50(10):3093-103 [15476205.001]
  • [Cites] Int J Clin Pharmacol Ther. 2004 Sep;42(9):496-503 [15487808.001]
  • [Cites] Immunol Rev. 2004 Dec;202:139-56 [15546391.001]
  • [Cites] Pharmacogenetics. 2004 Nov;14(11):733-9 [15564880.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):219-24 [15641066.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):280-6 [15657072.001]
  • [Cites] Ann Rheum Dis. 2005 Aug;64(8):1180-5 [15677700.001]
  • [Cites] Rheumatology (Oxford). 2005 Apr;44(4):547-52 [15695296.001]
  • [Cites] Rheumatology (Oxford). 2005 Jul;44(7):869-72 [15814578.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1063-8 [15818663.001]
  • [Cites] Arthritis Res Ther. 2005;7 Suppl 2:S4-14 [15833146.001]
  • [Cites] Curr Opin Rheumatol. 2005 May;17(3):299-304 [15838240.001]
  • [Cites] Genes Immun. 2005 Sep;6(6):459-61 [15875058.001]
  • [Cites] Pharmacol Rev. 2005 Jun;57(2):163-72 [15914465.001]
  • [Cites] Genes Immun. 2005 Sep;6(6):467-71 [15931231.001]
  • [Cites] Arthritis Rheum. 2005 Jun;52(6):1694-9 [15934099.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):419-26 [15958113.001]
  • [Cites] Rheumatology (Oxford). 2005 Oct;44(10):1263-6 [15998632.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1134-8 [16001646.001]
  • [Cites] Hum Genet. 2005 Oct;118(1):58-66 [16025348.001]
  • [Cites] Genes Immun. 2005 Dec;6(8):720-2 [16107870.001]
  • [Cites] Pediatr Nephrol. 2005 Nov;20(11):1566-71 [16133063.001]
  • [Cites] J Rheumatol. 2005 Sep;32(9):1650-3 [16142855.001]
  • [Cites] Rheumatol Int. 2006 Jun;26(8):726-31 [16220288.001]
  • [Cites] Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv2-14 [16239380.001]
  • [Cites] Exp Mol Pathol. 2006 Apr;80(2):141-6 [16248997.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3433-8 [16255021.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1317-9 [16273109.001]
  • [Cites] Arthritis Rheum. 2005 Dec;52(12):3813-8 [16320316.001]
  • [Cites] Am J Hum Genet. 2005 Dec;77(6):1044-60 [16380915.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):90-6 [16385500.001]
  • [Cites] Ann Rheum Dis. 2006 Sep;65(9):1213-8 [16439441.001]
  • [Cites] Arthritis Rheum. 2006 Feb;54(2):607-12 [16447238.001]
  • [Cites] Rheumatology (Oxford). 2006 Jul;45(7):804-7 [16449362.001]
  • [Cites] Arthritis Res Ther. 2006;8(2):R34 [16469113.001]
  • [Cites] Arthritis Rheum. 2006 Apr;54(4):1087-95 [16572443.001]
  • [Cites] Arthritis Rheum. 2006 Apr;54(4):1117-21 [16572446.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R75 [16635271.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R79 [16646982.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R105 [16817978.001]
  • [Cites] Can J Physiol Pharmacol. 2006 Jan;84(1):15-20 [16845886.001]
  • [Cites] Eur J Clin Pharmacol. 2006 Nov;62(11):933-7 [16932953.001]
  • [Cites] Biomed Pharmacother. 2006 Dec;60(10):678-87 [17071051.001]
  • [Cites] Rheumatol Int. 2007 Jul;27(9):827-33 [17265154.001]
  • [Cites] Scand J Rheumatol. 2006 Nov-Dec;35(6):435-40 [17343250.001]
  • [Cites] Nat Immunol. 2007 Apr;8(4):345-50 [17375096.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):4901-7 [17404271.001]
  • [Cites] Rheumatology (Oxford). 2007 Jun;46(6):1034-5 [17409133.001]
  • [Cites] Ann Rheum Dis. 2007 Nov;66(11):1525-30 [17456524.001]
  • [Cites] Pharmacogenet Genomics. 2007 Jun;17(6):383-90 [17502830.001]
  • [Cites] Nat Rev Immunol. 2007 Jun;7(6):429-42 [17525752.001]
  • [Cites] Ann Intern Med. 2007 Jun 5;146(11):797-808 [17548411.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):784-6 [17591062.001]
  • [Cites] Ann Rheum Dis. 2008 Mar;67(3):358-63 [17666451.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):465-71 [17681167.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1199-209 [17804836.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):977-86 [17804842.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4704-10 [17878369.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1431-3 [17982455.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1477-82 [17982456.001]
  • [Cites] Clin Exp Rheumatol. 2007 Sep-Oct;25(5):775-81 [18078632.001]
  • [Cites] J Hum Genet. 2008;53(2):163-73 [18087673.001]
  • [Cites] J Korean Med Sci. 2007 Dec;22(6):973-80 [18162709.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1663-9 [18250114.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):399-402 [18263596.001]
  • [Cites] Arthritis Res Ther. 2008;10(1):R26 [18307784.001]
  • [Cites] Mol Med. 2008 May-Jun;14(5-6):293-300 [18309376.001]
  • [Cites] Rheumatol Int. 2008 Jul;28(9):901-8 [18309487.001]
  • [Cites] Arthritis Res Ther. 2008;10(2):205 [18394179.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1211-5 [18438835.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1275-83 [18438843.001]
  • [Cites] Arthritis Res Ther. 2008;10(3):R52 [18462498.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Sep;64(9):871-6 [18496682.001]
  • [Cites] Arthritis Rheum. 2008 Jul;58(7):1974-80 [18576336.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Nov;64(11):1057-68 [18607581.001]
  • [Cites] Hum Immunol. 2008 Sep;69(9):567-71 [18625278.001]
  • [Cites] Ann Rheum Dis. 2009 Jun;68(6):898-903 [18633125.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):532-7 [18680473.001]
  • [Cites] Hum Mol Genet. 2008 Nov 15;17(22):3532-8 [18713756.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2598-602 [18759272.001]
  • [Cites] Ann Rheum Dis. 2009 Oct;68(10):1547-52 [18930989.001]
  • [Cites] Annu Rev Pathol. 2009;4:417-34 [18954286.001]
  • [Cites] Genes Immun. 2009 Mar;10(2):101-11 [18987647.001]
  • [Cites] Rheumatol Int. 2009 May;29(7):793-6 [19034456.001]
  • [Cites] Arthritis Rheum. 2009 Jan;60(1):30-8 [19116921.001]
  • [Cites] Pharmacogenomics. 2009 Feb;10(2):303-9 [19207032.001]
  • [Cites] J Rheumatol. 2009 Mar;36(3):539-45 [19208607.001]
  • [Cites] Arthritis Res Ther. 2009;11(2):R42 [19292917.001]
  • [Cites] Curr Opin Rheumatol. 2009 May;21(3):244-50 [19342956.001]
  • [Cites] Curr Opin Rheumatol. 2009 May;21(3):262-71 [19365266.001]
  • [Cites] Pharmacogenomics J. 2009 Jun;9(3):161-7 [19365401.001]
  • [Cites] Ann Rheum Dis. 2010 Mar;69(3):561-6 [19401279.001]
  • [Cites] Arthritis Rheum. 2009 May;60(5):1255-60 [19404967.001]
  • [Cites] Hum Mol Genet. 2009 Jul 15;18(14):2693-9 [19417005.001]
  • [Cites] Immunol Rev. 2009 May;229(1):307-21 [19426230.001]
  • [Cites] Pharmacol Rep. 2009 Mar-Apr;61(2):281-7 [19443940.001]
  • [Cites] Arthritis Res Ther. 2009;11(3):R70 [19445664.001]
  • [Cites] Ann Rheum Dis. 2010 Apr;69(4):666-70 [19470526.001]
  • [Cites] Mol Biol Rep. 2010 Jan;37(1):141-7 [19479340.001]
  • [Cites] Arthritis Res Ther. 2009;11(3):R99 [19563633.001]
  • [Cites] Arthritis Rheum. 2009 Sep;60(9):2577-84 [19714643.001]
  • [Cites] Nat Rev Rheumatol. 2009 Oct;5(10):531-41 [19798027.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(4):CD007277 [19821401.001]
  • [Cites] Rheumatol Int. 2010 Mar;30(5):661-6 [19588142.001]
  • (PMID = 23226040.001).
  • [ISSN] 1178-7066
  • [Journal-full-title] Pharmacogenomics and personalized medicine
  • [ISO-abbreviation] Pharmgenomics Pers Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3513198
  • [Keywords] NOTNLM ; pharmacogenetics / rheumatoid arthritis / susceptibility genes
  •  go-up   go-down


3. Kim MK, Park JW, Park SH, Bang SM, Chung JG, Ahn JY, Baek HJ: Neutrophilic myositis without cutaneous involvement as the first manifestation of acute myeloid leukemia. Korean J Intern Med; 2005 Dec;20(4):346-8
MedlinePlus Health Information. consumer health - Myositis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic myositis without cutaneous involvement as the first manifestation of acute myeloid leukemia.
  • Herein, we report a case of acute febrile neutrophilic myositis, without cutaneous involvement, as the first manifestation of acute myeloid leukemia.
  • All culture reports were negative, and he was finally diagnosed as having acute febrile neutrophilic myositis, associated with acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Myositis / etiology. Neutrophils / metabolism
  • [MeSH-minor] Adult. Fever / etiology. Humans. Male

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myositis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hematol. 2000 Feb;63(2):94-8 [10629576.001]
  • [Cites] Clin Dermatol. 2000 May-Jun;18(3):265-82 [10856659.001]
  • [Cites] J Am Acad Dermatol. 2001 Jan;44(1):137-9 [11148492.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):397-8 [12185512.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1887-97 [3058878.001]
  • [Cites] Semin Arthritis Rheum. 1988 Feb;17(3):143-53 [3072677.001]
  • [Cites] Hum Pathol. 1995 Jun;26(6):687-90 [7774902.001]
  • [Cites] Br J Dermatol. 1964 Aug-Sep;76:349-56 [14201182.001]
  • (PMID = 16491836.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891084
  •  go-up   go-down


Advertisement
4. Tafaghodi F, Aghighi Y, Rokni Yazdi H, Shakiba M, Adibi A: Predictive plain X-ray findings in distinguishing early stage acute lymphoblastic leukemia from juvenile idiopathic arthritis. Clin Rheumatol; 2009 Nov;28(11):1253-8
MedlinePlus Health Information. consumer health - Juvenile Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive plain X-ray findings in distinguishing early stage acute lymphoblastic leukemia from juvenile idiopathic arthritis.
  • Acute lymphoblastic leukemia (ALL) presenting with musculoskeletal pain may be difficult to distinguish from juvenile idiopathic arthritis (JIA).
  • [MeSH-major] Arthritis, Juvenile / radiography. Arthrography / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiography
  • [MeSH-minor] Adolescent. Bone Diseases, Metabolic / etiology. Bone Diseases, Metabolic / radiography. Bone and Bones / pathology. Bone and Bones / radiography. Child. Child, Preschool. Diagnosis, Differential. Edema / etiology. Edema / radiography. Female. Humans. Joints / pathology. Male


5. Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, Hervé M, Meffre E, Oscier DG, Vlassara H, Scofield RH, Chen Y, Allen SL, Kolitz J, Rai KR, Chu CC, Chiorazzi N: Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med; 2008 Nov-Dec;14(11-12):665-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation.
  • Chronic lymphocytic leukemia (CLL) represents the outgrowth of a CD5(+) B cell.
  • Its etiology is unknown.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2004 Aug 16;200(4):519-25 [15314077.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5122-9 [18812466.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2879-85 [15217826.001]
  • [Cites] J Exp Med. 1981 Mar 1;153(3):694-705 [7252411.001]
  • [Cites] J Immunol. 1982 Jun;128(6):2779-87 [6176652.001]
  • [Cites] Nature. 1987 Aug 27-Sep 2;328(6133):805-11 [3498121.001]
  • [Cites] J Exp Med. 1989 Jan 1;169(1):255-68 [2462608.001]
  • [Cites] J Autoimmun. 1988 Oct;1(5):469-81 [2473761.001]
  • [Cites] Blood. 1990 Aug 1;76(3):562-9 [2378986.001]
  • [Cites] Int Immunol. 1990;2(6):515-20 [1707658.001]
  • [Cites] Free Radic Biol Med. 1991;11(1):81-128 [1937131.001]
  • [Cites] J Exp Med. 1992 Feb 1;175(2):397-404 [1370683.001]
  • [Cites] J Immunol. 1993 Jun 1;150(11):4966-77 [8496598.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1083-6 [8145031.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1317-30 [7511686.001]
  • [Cites] J Immunol. 1994 Jun 15;152(12):5988-96 [8207223.001]
  • [Cites] Int Immunol. 1997 Jan;9(1):27-41 [9043945.001]
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1435-45 [9126924.001]
  • [Cites] Clin Geriatr Med. 1997 May;13(2):245-9 [9115449.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6347-52 [10339590.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] J Exp Med. 2004 Dec 6;200(11):1359-70 [15583011.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] J Biochem. 2005 Feb;137(2):157-66 [15749830.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1636-43 [15902303.001]
  • [Cites] J Leukoc Biol. 2006 Mar;79(3):489-98 [16365157.001]
  • [Cites] Immunity. 2006 Apr;24(4):429-38 [16618601.001]
  • [Cites] Blood. 2007 Jan 1;109(1):259-70 [16985177.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2198-201 [17082317.001]
  • [Cites] Nat Immunol. 2007 May;8(5):487-96 [17417641.001]
  • [Cites] Eur J Immunol. 2007 Aug;37(8):2138-47 [17615580.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1524-33 [17959859.001]
  • [Cites] Arthritis Res Ther. 2007;9(6):222 [18086320.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3838-48 [18223168.001]
  • [Cites] J Intern Med. 2008 May;263(5):479-88 [18410591.001]
  • [Cites] Biochemistry. 1999 Dec 21;38(51):16802-9 [10606512.001]
  • [Cites] Immunol Rev. 2000 Jun;175:70-9 [10933592.001]
  • [Cites] Atherosclerosis. 2001 May;156(1):133-44 [11369006.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):675-80 [11477402.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] J Exp Med. 2002 Jan 21;195(2):181-8 [11805145.001]
  • [Cites] Annu Rev Immunol. 2003;21:841-94 [12615894.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):6151-7 [12794145.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1374-7 [12920303.001]
  • [Cites] Mol Immunol. 2004 Jan;40(10):647-60 [14644091.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6692-700 [15153485.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4389-95 [14962897.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4087-93 [12010811.001]
  • [Cites] Clin Exp Immunol. 2008 Jul;153(1):102-16 [18510544.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2499-504 [15217828.001]
  • (PMID = 19009014.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR018535; United States / NCI NIH HHS / CA / R01 CA087956; United States / NCI NIH HHS / CA / CA87956; United States / NCRR NIH HHS / RR / RR018535
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Autoantigens; 0 / Epitopes
  • [Other-IDs] NLM/ PMC2582860
  •  go-up   go-down


6. Landgren O, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, Linet MS, Goldin LR: Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood; 2006 Jul 1;108(1):292-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries.
  • A population-based case-control study was conducted to evaluate risk of developing chronic lymphocytic leukemia (CLL) associated with personal and/or family history of autoimmune and related diseases.
  • If our results are confirmed, mechanistic studies examining how pernicious anemia might promote increased occurrence of CLL and how chronic rheumatic heart disease protects against CLL, perhaps related to long-term antibiotics use, may provide insights to the as-yet-unknown etiology of CLL.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2005 Jul 9-15;366(9480):155-68 [16005340.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 6;97(7):543-4; author reply 544-5 [15812083.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2090-3 [16322480.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2889-94 [16317103.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3095-8 [16395700.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1353-7 [10755414.001]
  • [Cites] Blood. 2000 May 1;95(9):2786-92 [10779422.001]
  • [Cites] Eur J Haematol. 2000 Aug;65(2):114-7 [10966171.001]
  • [Cites] Acta Oncol. 2001;40(6):772-7 [11765074.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):963-70 [12687538.001]
  • [Cites] Blood. 2004 May 1;103(9):3490-5 [14695232.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Natl Cancer Inst. 2004 May 19;96(10):780-4 [15150306.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4389-95 [14962897.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] Scand J Haematol. 1976 Nov;17(5):395-7 [1006164.001]
  • [Cites] Medicine (Baltimore). 1980 Sep;59(5):323-34 [7001171.001]
  • [Cites] Acta Radiol Oncol. 1984;23(5):305-13 [6095600.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] J Natl Cancer Inst. 1986 Aug;77(2):371-8 [3461199.001]
  • [Cites] Br J Cancer. 1987 Jul;56(1):79-82 [3304389.001]
  • [Cites] Int J Epidemiol. 1988 Sep;17(3):512-3 [3209328.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):353-7 [3222144.001]
  • [Cites] Am J Epidemiol. 1989 Oct;130(4):655-64 [2773914.001]
  • [Cites] Ann Intern Med. 1990 Oct 1;113(7):525-39 [2203293.001]
  • [Cites] Leuk Res. 1991;15(5):305-14 [2046383.001]
  • [Cites] Cancer Causes Control. 1992 Sep;3(5):449-56 [1525326.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:152-4 [1434818.001]
  • [Cites] Cancer Causes Control. 1993 Jul;4(4):361-8 [8347786.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2378-85 [8162584.001]
  • [Cites] Eur J Epidemiol. 1994 Apr;10(2):211-3 [7813700.001]
  • [Cites] Genet Epidemiol. 1998;15(3):225-36 [9593110.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1941-7 [15483675.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):449-52 [16049983.001]
  • (PMID = 16527887.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1895837
  •  go-up   go-down


7. Wang SS, Abdou AM, Morton LM, Thomas R, Cerhan JR, Gao X, Cozen W, Rothman N, Davis S, Severson RK, Bernstein L, Hartge P, Carrington M: Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood; 2010 Jun 10;115(23):4820-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology.
  • Our results support a role for HLA in the etiology of NHL and its subtypes.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 2002 Jan;122(1-2):140-5 [11777553.001]
  • [Cites] Leukemia. 2010 May;24(5):1055-8 [20147981.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4273-6 [15383555.001]
  • [Cites] Nature. 1975 Jul 3;256(5512):50-2 [1079575.001]
  • [Cites] J Hepatol. 1997 Mar;26(3):503-7 [9075656.001]
  • [Cites] J Hepatol. 1997 Aug;27(2):259-64 [9288598.001]
  • [Cites] Hepatology. 1998 Jan;27(1):240-4 [9425943.001]
  • [Cites] Science. 1999 Mar 12;283(5408):1748-52 [10073943.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Nat Genet. 2006 Oct;38(10):1166-72 [16998491.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]
  • [Cites] J Viral Hepat. 2007 Dec;14(12):841-8 [18070287.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Nov;23(11):1716-21 [18761557.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Arthritis Rheum. 2010 May;62(5):1236-45 [20131291.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):35-40 [12807943.001]
  • (PMID = 20385791.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / PC / N02-PC-71105; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / Intramural NIH HHS / / ; None / None / / N01 PC065064; United States / PHS HHS / / HHSN261200800001E; United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CA / HHSN261200800001E
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II
  • [Other-IDs] NLM/ PMC2890176
  •  go-up   go-down


8. Raimbourg J, Cormier G, Stéphane Varin, Tanguy G, Bleher Y, Maisonneuve H: Hairy-cell leukemia with inaugural joint manifestations. Joint Bone Spine; 2009 Jul;76(4):416-20
MedlinePlus Health Information. consumer health - Osteoarthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hairy-cell leukemia with inaugural joint manifestations.
  • Hairy-cell leukemia is a chronic B-cell malignancy seen in adults.
  • The identification of hairy cells in the joint fluid establishes the diagnosis of leukemia-related arthritis.
  • One of the main differential diagnoses is Felty's syndrome, which combines rheumatoid arthritis, splenomegaly, and neutropenia.
  • Among 27 patients with hairy-cell leukemia managed at our institution, 1 presented with joint manifestations.
  • [MeSH-major] Leukemia, Hairy Cell / complications. Osteoarthritis / diagnosis. Osteoarthritis / etiology

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19541526.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Singh YP, Agarwal V, Krishnani N, Misra R: Enthesitis-related arthritis in Kikuchi-Fujimoto disease. Mod Rheumatol; 2008;18(5):492-5
MedlinePlus Health Information. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enthesitis-related arthritis in Kikuchi-Fujimoto disease.
  • Articular manifestations in the form of arthralgias are common but frank arthritis is distinctly rare and dactylitis has not been reported yet.
  • Herein, we describe a young boy who presented with arthritis and dactylitis as the initial manifestation of KFD.
  • Two years earlier he presented with arthritis of the knee and ankle joints, which lasted for 12 months.
  • Work-up for infectious etiology, systemic lupus erythematosus and leukemia and lymphoma was negative.
  • Fever, lymphadenopathy and leukopenia dissipated with nonsteroidal anti inflammatory drug therapy, but the arthritis persisted.
  • A trial of methotrexate led to the resolution of the arthritis.

  • Genetic Alliance. consumer health - Kikuchi disease.
  • Genetic Alliance. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470474.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Worch J, Ritter J, Frühwald MC: Presentation of acute promyelocytic leukemia as granulocytic sarcoma. Pediatr Blood Cancer; 2008 Mar;50(3):657-60
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation of acute promyelocytic leukemia as granulocytic sarcoma.
  • This extramedullary tumor can present before, concurrent with or after the diagnosis of acute myeloid leukemia.
  • GS is extremely uncommon in acute promyelocytic leukemia (APL).
  • [MeSH-major] Diagnostic Errors. Leukemia, Promyelocytic, Acute / complications. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arthritis, Psoriatic / diagnosis. Biomarkers, Tumor / analysis. Female. Humans. Oncogene Proteins, Fusion / analysis. Osteolysis / etiology. Osteomyelitis / diagnosis. Remission Induction. Shoulder Pain / etiology. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17437290.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin
  •  go-up   go-down


11. Jønsson V, Bock JE, Hilden J, Houlston RS, Wiik A: The influence of pregnancy on the development of autoimmunity in chronic lymphocytic leukemia. Leuk Lymphoma; 2006 Aug;47(8):1481-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of pregnancy on the development of autoimmunity in chronic lymphocytic leukemia.
  • To examine whether pregnancy influences the development of autoimmunity in chronic lymphocytic leukemia (CLL), we studied 591 consecutive CLL patients (202 post-menopausal women and 389 men).
  • Coombs' positive autoimmune anemia, a gastric ulcer with parietal cell autoantibodies and idiopathic thrombocytopenic purpura were equally common in women and men, whereas autoimmune thyroiditis, Sjögren's syndrome, rheumatoid arthritis and systemic lupus erythematosus were seen in higher rates in women than in men.
  • [MeSH-major] Autoimmunity. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Pregnancy Complications, Neoplastic / immunology
  • [MeSH-minor] Autoantibodies / blood. Autoimmune Diseases / etiology. Female. Follow-Up Studies. Gravidity. Humans. Male. Pregnancy. Sexual Behavior

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Aug;47(8):1443-4 [16966247.001]
  • [CommentIn] Leuk Lymphoma. 2006 Aug;47(8):1445-6 [16966248.001]
  • (PMID = 16966257.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies
  •  go-up   go-down


12. Naithani R, Rai S, Choudhry VP: Septic arthritis of hip in a neutropenic child caused by Salmonella typhi. J Pediatr Hematol Oncol; 2008 Feb;30(2):182-4
MedlinePlus Health Information. consumer health - Infectious Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Septic arthritis of hip in a neutropenic child caused by Salmonella typhi.
  • A 5-year-old male child was undergoing chemotherapy for pre-B acute lymphoblastic leukemia.
  • He developed Salmonella typhi arthritis of his left hip joint during neutropenic phase.
  • Infection was successfully treated with intravenous antibiotics without surgical management. S. typhi is a potential cause of arthritis, especially in immunocompromised children.
  • More than 100 other cases of Salmonella arthritis are reviewed and reveal a disease primarily of children and young adults with a favorable treatment response.
  • [MeSH-major] Arthritis, Infectious / etiology. Hip Joint. Neutropenia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Typhoid Fever / complications

  • Genetic Alliance. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376276.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


13. Choi BR, Ahn MJ, Lee WS, Kim TH, Bae SC, Jun JB: Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy. Rheumatol Int; 2005 May;25(4):311-3
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy.
  • Acute leukemia is uncommonly seen with rheumatoid arthritis during or following treatment with low-dose methotrexate, a safe and effective treatment for the arthritic condition.
  • We describe here a 68-year-old woman with rheumatoid arthritis who developed acute erythroleukemia during low-dose methotrexate therapy (total dose 1702.5 mg).
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Leukemia, Erythroblastic, Acute / etiology. Methotrexate / therapeutic use


14. Chiappetta N, Gruber B: Remitting seronegative symmetrical synovitis with pitting edema associated with acute myeloid leukemia. J Rheumatol; 2005 Aug;32(8):1613-4
MedlinePlus Health Information. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remitting seronegative symmetrical synovitis with pitting edema associated with acute myeloid leukemia.
  • Patients present with a polyarthritis similar to rheumatoid arthritis.
  • We describe a case of an elderly man presenting with RS3PE who developed acute myeloid leukemia.
  • [MeSH-major] Edema / etiology. Leukemia, Myeloid / complications. Paraneoplastic Syndromes / etiology. Synovitis / etiology

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Synovitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078344.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


15. Viny AD, Lichtin A, Pohlman B, Loughran T, Maciejewski J: Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leuk Lymphoma; 2008 May;49(5):932-8
Genetic Alliance. consumer health - Leukemia, B-cell, chronic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia.
  • T cell large granular lymphocyte leukemia (T-LGL) is characterised by semiautonomous proliferation of monoclonal cytotoxic T lymphocytes, which can result in neutropenia, splenomegaly, and is associated with various autoimmune disorders, particularly rheumatoid arthritis.
  • The coexistence of T-LGL leukemia with B cell abnormalities has previously been identified in case reports.
  • We identified coexisting B cell dyscrasias in 17 T-LGL patients (27% of total), of whom 12 had monoclonal gammopathy of unknown significance (MGUS) (19%), and 5 had chronic lymphocytic leukemia (CLL) (8%).
  • Additionally, polyclonal hypergammaglobulinemia or hypogammaglobulinemia was found in 10 additional LGL leukemia patients bringing the total frequency of B cell abnormalities in T-LGL leukemia to 43% in our cohort.
  • [MeSH-major] B-Lymphocytes / pathology. Leukemia, Large Granular Lymphocytic / etiology. Lymphoproliferative Disorders / complications
  • [MeSH-minor] Agammaglobulinemia / complications. Comorbidity. Humans. Hypergammaglobulinemia / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, Follicular / complications. Monoclonal Gammopathy of Undetermined Significance / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 May;49(5):845-6 [18464104.001]
  • (PMID = 18452068.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Senel S, Kaya E, Aydogdu I, Erkurt MA, Kuku I: Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature. Rheumatol Int; 2006 Jul;26(9):857-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature.
  • We report four patients with rheumatic disease (RD) and chronic myelogenous leukemia (CML).
  • In two patients with Behcet's disease (BD) and rheumatoid arthritis (RA), CML developed after RD, in two patients with diffuse cutaneous systemic sclerosis and spondyloarthropathy, RD was diagnosed after CML.
  • [MeSH-major] Behcet Syndrome / etiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology. Rheumatic Diseases / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Hydroxyurea / therapeutic use. Middle Aged. Scleroderma, Systemic / etiology. Spondylarthritis / etiology

  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404564.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 25
  •  go-up   go-down


17. Karimova EJ, Kaste SC: MR imaging of osteonecrosis of the knee in children with acute lymphocytic leukemia. Pediatr Radiol; 2007 Nov;37(11):1140-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of osteonecrosis of the knee in children with acute lymphocytic leukemia.
  • This essay illustrates various patterns of progression of osteonecrosis of the knee and the relationship between early MR imaging findings and radiologic outcome in children with acute lymphocytic leukemia.
  • Such abnormalities must be distinguished from osteonecrosis, which can lead to joint collapse and predispose to secondary arthritis.
  • [MeSH-major] Image Enhancement / methods. Knee Joint / pathology. Magnetic Resonance Imaging / methods. Osteonecrosis / diagnosis. Osteonecrosis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768614.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA21765; United States / NCI NIH HHS / CA / R01-CA20180
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 27
  •  go-up   go-down


18. Viny AD, Clemente MJ, Jasek M, Askar M, Ishwaran H, Nowacki A, Zhang A, Maciejewski JP: MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia. Haematologica; 2010 Oct;95(10):1713-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia.
  • BACKGROUND: Large granular lymphocyte leukemia is a semi-autonomous clonal proliferation of cytotoxic T cells accompanied by immune cytopenias and various autoimmune conditions.
  • DESIGN AND METHODS: To investigate a non-mendelian genetic predisposition to large granular lymphocyte leukemia, we used a step-wise method for gene discovery.
  • RESULTS: Our analysis found an association with MICA, a non-peptide-presenting, tightly regulated, stress-induced MHC-like molecule and cognate receptor for NKG2D, found abundantly on large granular lymphocyte leukemia cells.
  • Sequencing of germline DNA revealed a higher frequency of MICA*00801/A5.1 in patients with large granular lymphocyte leukemia than in matched controls (64% versus 41%, P<0.001, homozygous 40% versus 15%, P<0.001).
  • Flow cytometry was employed to determine the expression of MICA within hematologic compartments, showing that the signal intensity of MICA was increased in granulocytes from neutropenic patients with large granular lymphocyte leukemia in comparison with that in controls (P=0.033).
  • Finally, large granular lymphocyte leukemia cells were able to selectively kill MICA(+) Ba/F3 lymphocytes transfected with human MICA*019 in a dose-dependent manner compared to naïve cells (P<0.001), an effect mitigated by administration of an anti-NKG2D antibody (P=0.033).
  • CONCLUSIONS: Our results illustrate that MICA-NKG2D played a role in disease pathogenesis in the majority of patients in our cohort of cases of large granular lymphocyte leukemia and further investigation into this signaling axis may provide potent therapeutic targets.

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1985 Feb;102(2):169-75 [3966754.001]
  • [Cites] Allergy. 1979 Oct;34(5):275-81 [121045.001]
  • [Cites] Crit Rev Immunol. 1990;10(4):307-28 [2285459.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):624-6 [9125243.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):672-5 [9930071.001]
  • [Cites] Immunogenetics. 1999 Jul;49(7-8):605-12 [10369917.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Transpl Immunol. 2005 Aug;14(3-4):175-82 [15982560.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7502-8 [16103105.001]
  • [Cites] J Virol. 2008 May;82(9):4585-94 [18287244.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):932-8 [18452068.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3226-34 [19075187.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2769-80 [15914562.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;298:121-38 [16329186.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4834-40 [16484592.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3143-9 [16920952.001]
  • [Cites] J Gen Virol. 2007 Jan;88(Pt 1):242-50 [17170457.001]
  • [Cites] Cell Cycle. 2006 Nov;5(22):2571-4 [17172839.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):961-9 [17202358.001]
  • [Cites] Br J Haematol. 2007 Jan;136(2):237-48 [17156396.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):232-40 [16857416.001]
  • [Cites] Eur J Immunol. 2007 Jul;37(7):1938-53 [17557375.001]
  • [Cites] Scand J Immunol. 2007 Aug-Sep;66(2-3):320-8 [17635809.001]
  • [Cites] J Biol Chem. 2007 Oct 19;282(42):30658-66 [17690100.001]
  • [Cites] Am J Med. 2000 Jun 15;108(9):744-5 [10924655.001]
  • [Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1610-6 [17993614.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):255-60 [11224526.001]
  • [Cites] Hum Immunol. 2001 Jun;62(6):620-31 [11390037.001]
  • [Cites] Hum Immunol. 2001 Jun;62(6):632-8 [11390038.001]
  • [Cites] Blood. 2001 Jul 15;98(2):483-5 [11435321.001]
  • [Cites] Immunity. 2001 Jul;15(1):83-93 [11485740.001]
  • [Cites] Immunogenetics. 2002 Feb;53(10-11):989-91 [11862400.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2971-6 [11854468.001]
  • [Cites] J Rheumatol. 2002 May;29(5):973-8 [12022360.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1236-40 [12133944.001]
  • [Cites] Nature. 2002 Oct 17;419(6908):734-8 [12384702.001]
  • [Cites] Hematology. 2003 Jun;8(3):173-81 [12745651.001]
  • [Cites] Biotechniques. 2003 Oct;35(4):758-60, 762-5 [14579741.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):449-53 [14617004.001]
  • [Cites] Ann N Y Acad Sci. 2003 Nov;1005:314-8 [14679082.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1960-9 [14734782.001]
  • [Cites] Genes Immun. 2004 Aug;5(5):371-4 [15164101.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2470-8 [15294961.001]
  • [Cites] Blood. 1988 Mar;71(3):822-4 [3345349.001]
  • (PMID = 20460636.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K24 HL077522; United States / PHS HHS / / U54 655365070704; United States / Howard Hughes Medical Institute / / ; United States / PHS HHS / / R01 655365071402; United States / PHS HHS / / K24 655365071503
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KLRK1 protein, human; 0 / MHC class I-related chain A; 0 / NK Cell Lectin-Like Receptor Subfamily K
  • [Other-IDs] NLM/ PMC2948097
  •  go-up   go-down


19. Gupta D, Singh S, Suri D, Ahluwalia J, Das R, Varma N: Arthritic presentation of acute leukemia in children: experience from a tertiary care centre in North India. Rheumatol Int; 2010 Apr;30(6):767-70
MedlinePlus Health Information. consumer health - Juvenile Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arthritic presentation of acute leukemia in children: experience from a tertiary care centre in North India.
  • The objectives of this study are to highlight the arthritic presentation of acute lymphoblastic leukemia (ALL) in children and to delineate features that could help differentiate it from juvenile idiopathic arthritis (JIA).
  • [MeSH-major] Arthritis / diagnosis. Arthritis / etiology. Arthritis, Juvenile / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Anemia / etiology. Anemia / physiopathology. Arthralgia / etiology. Arthralgia / physiopathology. Biomarkers / analysis. Bone Marrow Examination / standards. Case-Control Studies. Child. Child, Preschool. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Humans. India. Leukopenia / etiology. Leukopenia / physiopathology. Lymphatic Diseases / etiology. Lymphocyte Count. Lymphocytes / pathology. Male. Pain / etiology. Pain / physiopathology. Pain Measurement. Splenomegaly / etiology. Thrombocytopenia / etiology

  • MedlinePlus Health Information. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633857.001).
  • [ISSN] 1437-160X
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


20. Wlodarski MW, Nearman Z, Jankowska A, Babel N, Powers J, Leahy P, Volk HD, Maciejewski JP: Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol; 2008 Mar;83(3):589-601
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia.
  • T cell large granular lymphocyte leukemia (T-LGL) is a chronic clonal lymphoproliferation of CTL.
  • Here, we focus our analysis on immunological networks, as immune mechanisms play a prominent role in the etiology of bone marrow failure in T-LGL.
  • Despite a strikingly similar gene expression profile between T-LGL clones and their healthy counterparts, important phenotypic differences were identified, including up-modulation of TNFRS9, myeloid cell leukemia sequence 1, IFN-gamma, and IFN-gamma-related genes, and several integrins/adhesion molecules.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Neurosci. 2002 Jun;25(6):313-9 [12086750.001]
  • [Cites] J Clin Invest. 2002 Jul;110(2):185-92 [12122110.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1449-53 [12149230.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):33-9 [12469182.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3198-204 [12480700.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Nat Immunol. 2003 May;4(5):410-5 [12719730.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):185-95 [12876667.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):213-20 [12876670.001]
  • [Cites] J Exp Med. 1997 Nov 3;186(9):1407-18 [9348298.001]
  • [Cites] J Exp Med. 1998 Mar 2;187(5):763-74 [9480986.001]
  • [Cites] Br J Haematol. 1998 May;101(2):318-24 [9609528.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):278-84 [9920952.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1151-8 [10725328.001]
  • [Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]
  • [Cites] Arthritis Rheum. 2000 Apr;43(4):834-43 [10765928.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1021-9 [10910918.001]
  • [Cites] Eur J Immunol. 2000 Jul;30(7):1797-806 [10940868.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):4127-32 [11034425.001]
  • [Cites] J Immunol. 2000 Nov 15;165(10):5729-37 [11067931.001]
  • [Cites] Immunology. 2001 Jan;102(1):44-52 [11168636.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2364-71 [11160294.001]
  • [Cites] Annu Rev Immunol. 2001;19:65-91 [11244031.001]
  • [Cites] Leuk Res. 2001 Aug;25(8):699-708 [11397476.001]
  • [Cites] Blood. 2001 Jul 1;98(1):165-73 [11418476.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2817-27 [11675356.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1861-8 [11696446.001]
  • [Cites] Exp Hematol. 2001 Nov;29(11):1270-7 [11698122.001]
  • [Cites] Curr Dir Autoimmun. 2002;5:1-29 [11826753.001]
  • [Cites] Eur J Immunol. 2002 Feb;32(2):521-9 [11828369.001]
  • [Cites] Hematol J. 2002;3(1):32-7 [11960393.001]
  • [Cites] Leukemia. 1999 Feb;13(2):230-40 [10025897.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9220-9 [15516985.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):529-35 [15645140.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):381-7 [15725471.001]
  • [Cites] J Autoimmun. 2005 Aug;25(1):13-20 [15998581.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2002-10 [15941918.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6035-46 [16155610.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2769-80 [15914562.001]
  • [Cites] Virol J. 2004;1:5 [15507126.001]
  • [Cites] PLoS Med. 2005 Dec;2(12):e343 [16253012.001]
  • [Cites] Blood. 2006 Jan 1;107(1):167-75 [16131564.001]
  • [Cites] Oncologist. 2006 Mar;11(3):263-73 [16549811.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4834-40 [16484592.001]
  • [Cites] J Clin Lab Immunol. 2004-2005;53:1-12 [16805321.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2632-41 [16614248.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Jun;19(6):497-502 [12882659.001]
  • [Cites] Nat Immunol. 2003 Sep;4(9):835-42 [12942084.001]
  • [Cites] J Leukoc Biol. 2003 Sep;74(3):331-43 [12949236.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):515-24 [14519385.001]
  • [Cites] BMC Bioinformatics. 2002 Aug 23;3:22 [12194703.001]
  • [Cites] Nature. 2003 Dec 11;426(6967):671-6 [14668867.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1960-9 [14734782.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Feb;20(2):227-33 [15018711.001]
  • [Cites] J Gen Virol. 2004 May;85(Pt 5):1065-76 [15105524.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1462-3 [14962933.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4818-27 [15122313.001]
  • [Cites] Exp Hematol. 2004 Sep;32(9):806-14 [15345281.001]
  • [Cites] J Immunol. 1981 Sep;127(3):1024-9 [6790607.001]
  • [Cites] Medicine (Baltimore). 1987 Sep;66(5):397-405 [3626848.001]
  • [Cites] Blood. 1988 Mar;71(3):822-4 [3345349.001]
  • [Cites] J Immunol. 1988 Sep 15;141(6):1963-9 [3049797.001]
  • [Cites] Leukemia. 1992 May;6(5):465-9 [1317489.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1116-9 [1355373.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1282-8 [7858258.001]
  • [Cites] Clin Exp Immunol. 1996 Apr;104(1):180-4 [8603525.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):158-62 [9052725.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):123-6 [9136951.001]
  • [Cites] Immunology. 1997 Jun;91(2):204-11 [9227318.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Int Rev Immunol. 1999;18(1-2):111-40 [10614741.001]
  • [Cites] Am J Dermatopathol. 2000 Feb;22(1):7-16 [10698209.001]
  • [Cites] Blood. 2002 Jul 1;100(1):178-83 [12070025.001]
  • (PMID = 18086899.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL073429-01A1; United States / NHLBI NIH HHS / HL / R01 HL073429; United States / NHLBI NIH HHS / HL / R01 HL 073429-01A1; United States / NHLBI NIH HHS / HL / R01 HL073429-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS83527; NLM/ PMC2629660
  •  go-up   go-down


21. Shah N, Zambidis ET: False-photosensitivity and transient hemiparesis following high-dose intravenous and intrathecal methotrexate for treatment of acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Jul;53(1):103-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-photosensitivity and transient hemiparesis following high-dose intravenous and intrathecal methotrexate for treatment of acute lymphoblastic leukemia.
  • We describe a patient who was treated with high-dose intravenous and intrathecal methotrexate for acute lymphoblastic leukemia, and who manifested a false photosensitivity reaction with no prior evidence of sun exposure.
  • The etiology of these events is obscure, but suggestive of a vasculitic or immune-mediated reaction to methotrexate.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • [Cites] Arch Argent Pediatr. 2008 Feb;106(1):42-6 [18636134.001]
  • [Cites] Cutis. 2000 Nov;66(5):379-82 [11107525.001]
  • [Cites] J Rheumatol. 1985 Apr;12(2):354-5 [4032407.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1845-50 [3465876.001]
  • [Cites] Cutis. 1987 Jan;39(1):49-51 [3802910.001]
  • [Cites] Neuropediatrics. 2008 Feb;39(1):46-50 [18504683.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2058-61 [2004323.001]
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 1):702-7 [10321597.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1688-95 [15569732.001]
  • [Cites] Semin Arthritis Rheum. 2006 Jun;35(6):388-95 [16765716.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):178-84 [17947226.001]
  • [Cites] Clin Exp Pharmacol Physiol Suppl. 1979;5:57-61 [318498.001]
  • (PMID = 19326416.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL077595-01; United States / NHLBI NIH HHS / HL / HL077595-05; United States / NHLBI NIH HHS / HL / K08 HL077595-01; United States / NHLBI NIH HHS / HL / K08 HL077595-05; United States / NHLBI NIH HHS / HL / HL077595-04; United States / NHLBI NIH HHS / HL / K08 HL077595-02; United States / NHLBI NIH HHS / HL / HL077595-02; United States / NHLBI NIH HHS / HL / K08 HL077595-03; United States / NHLBI NIH HHS / HL / K08 HL077595-04; United States / NHLBI NIH HHS / HL / K08 HL077595; United States / NHLBI NIH HHS / HL / HL077595-03
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleic Acid Synthesis Inhibitors; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS129680; NLM/ PMC3073488
  •  go-up   go-down


22. Zhao X, Zhou K, Wang HJ, Zhang L, Liu QG, Jing LP, Li HQ, Yang DL, Chu YL, Zhang FK: [The clinical and laboratory characteristics of T cell large granular lymphocyte leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Mar;30(3):179-82
Genetic Alliance. consumer health - Large granular lymphocyte leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical and laboratory characteristics of T cell large granular lymphocyte leukemia].
  • OBJECTIVE: To analyze the characteristics of T-cell large granular lymphocyte leukemia (T-LGLL).
  • Rheumatoid arthritis was not present in any patients.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic / diagnosis. Leukemia, Large Granular Lymphocytic / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunophenotyping. Immunosuppression. Male. Middle Aged. Red-Cell Aplasia, Pure / etiology. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642367.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, Shibuya M: Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood; 2006 Sep 15;108(6):1849-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages.
  • Vascular endothelial growth factor (VEGF) and VEGF receptor-1 (VEGFR-1/Flt-1) were shown to be involved in pathological angiogenesis, particularly rheumatoid arthritis (RA).
  • Pathological symptoms, such as synovial hyperplasia, inflammatory infiltrates, pannus formation, and cartilage/bone destruction, became milder in Vegfr-1 tk(-/-) mice compared with wild-type (Wt) mice in the human T-cell leukemia virus-1 (HTLV-1) pX-induced chronic models.
  • Treatment of this RA model with a small molecule inhibitor for VEGFR TK, KRN951, also attenuated the arthritis.
  • [MeSH-major] Arthritis, Rheumatoid / etiology. Vascular Endothelial Growth Factor Receptor-1 / metabolism

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709927.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


24. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC, Children's Oncology Group Pilot Study: Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol; 2008 Aug 1;26(22):3756-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
  • PURPOSE: To determine the tolerability and serum concentration of epratuzumab, a humanized monoclonal antibody targeting CD22, administered alone and in combination with reinduction chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL), and to preliminarily assess tumor targeting and efficacy.
  • Two dose-limiting toxicities occurred: one grade 4 seizure of unclear etiology and one asymptomatic grade 3 ALT elevation.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Oct;17(10):1967-72 [14513046.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3971-8 [18711187.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5327-34 [15328168.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Blood. 1993 Feb 1;81(3):602-9 [8427957.001]
  • [Cites] Cancer Immunol Immunother. 1993 Oct;37(5):293-8 [7691407.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):538-45 [8112889.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S [14506197.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Annu Rev Immunol. 1997;15:481-504 [9143697.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4846-50 [15570088.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5044-51 [15955901.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R74 [16630358.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53 [17069520.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2826-32 [17099879.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R129 [16859536.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3704-13 [17530024.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • (PMID = 18669463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / CD22 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab
  • [Other-IDs] NLM/ PMC2654811
  •  go-up   go-down


25. Shishido-Hara Y: Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease. Acta Neuropathol; 2010 Sep;120(3):403-17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease.
  • Recently, promyelocytic leukemia nuclear bodies (PML-NBs), punctuate structures for important nuclear functions in eukaryotic cells, were identified as an intranuclear target of JC virus infection.
  • Here, we review what we have learned since the disease entity establishment, including a look at recent progress in understanding the relationship between JC virus, etiology and PML-NBs.

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 2005 Apr;109(4):449-55 [15739098.001]
  • [Cites] N Engl J Med. 2005 Jul 28;353(4):375-81 [15947078.001]
  • [Cites] N Engl J Med. 2005 Jul 28;353(4):369-74 [15947079.001]
  • [Cites] N Engl J Med. 2005 Jul 28;353(4):362-8 [15947080.001]
  • [Cites] Clin Neurol Neurosurg. 2005 Oct;107(6):509-13 [16202824.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Dec 1;50(1):69-85 [15982744.001]
  • [Cites] Neurobiol Dis. 2005 Dec;20(3):656-65 [15964198.001]
  • [Cites] Am J Hematol. 2005 Dec;80(4):271-81 [16315252.001]
  • [Cites] N Engl J Med. 2006 Mar 2;354(9):924-33 [16510746.001]
  • [Cites] J Neurovirol. 2005;11 Suppl 3:16-22 [16540449.001]
  • [Cites] J Cell Biol. 2006 Jul 3;174(1):65-76 [16818720.001]
  • [Cites] Proteomics. 2006 Oct;6(20):5628-36 [16991198.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(2):101-7 [17143300.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1291-304 [17392168.001]
  • [Cites] Oncogene. 2000 Oct 5;19(42):4840-6 [11039901.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1115-20 [11048806.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1228-35 [11054380.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):921-9 [11079782.001]
  • [Cites] J Virol. 2001 Feb;75(4):1996-2001 [11160700.001]
  • [Cites] Trends Cell Biol. 2001 May;11(5):184-7 [11316590.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4287-93 [11358858.001]
  • [Cites] Clin Infect Dis. 2000 Jan;30(1):95-9 [10619739.001]
  • [Cites] J Virol. 2000 Feb;74(4):1840-53 [10644357.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):85-92 [10668898.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):394-5 [10746685.001]
  • [Cites] J Neurovirol. 2000 Apr;6(2):127-36 [10822326.001]
  • [Cites] J Virol. 1996 Mar;70(3):1512-20 [8627669.001]
  • [Cites] AIDS. 1996 Apr;10(4):353-8 [8728037.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7352-7 [8692997.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2023-35 [8952536.001]
  • [Cites] J Neurovirol. 1996 Dec;2(6):411-6 [8972423.001]
  • [Cites] J Med Virol. 1997 Apr;51(4):265-72 [9093939.001]
  • [Cites] Lancet. 1997 May 3;349(9061):1294 [9142067.001]
  • [Cites] J Med Virol. 1997 Jul;52(3):243-52 [9210031.001]
  • [Cites] J Neurovirol. 1995 Jun;1(2):195-206 [9222358.001]
  • [Cites] J Clin Microbiol. 1997 Sep;35(9):2288-92 [9276404.001]
  • [Cites] J Virol. 2004 Apr;78(7):3462-9 [15016869.001]
  • [Cites] J Virol. 2004 May;78(9):4884-91 [15078969.001]
  • [Cites] J Virol. 2004 Sep;78(18):9890-903 [15331723.001]
  • [Cites] Bioessays. 2004 Sep;26(9):963-77 [15351967.001]
  • [Cites] J Neurovirol. 2004 Aug;10(4):244-9 [15371154.001]
  • [Cites] Acta Neuropathol. 1965 Nov 18;5(2):215-24 [5886201.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1257-60 [4104715.001]
  • [Cites] Genomics. 2003 Aug;82(2):250-2 [12837275.001]
  • [Cites] J Med Virol. 2003 Sep;71(1):115-23 [12858417.001]
  • [Cites] Neurobiol Dis. 2003 Aug;13(3):230-7 [12901837.001]
  • [Cites] J Neurovirol. 2003 Aug;9(4):498-507 [12907394.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5181-91 [12910255.001]
  • [Cites] Cell Mol Life Sci. 2003 Jul;60(7):1427-39 [12943229.001]
  • [Cites] J Virol. 2003 Oct;77(19):10638-44 [12970448.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6517-23 [14528276.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):419-28 [14742248.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):269-79 [14970276.001]
  • [Cites] Ann Neurol. 1992 Apr;31(4):454-62 [1316734.001]
  • [Cites] J Virol. 1992 Oct;66(10):5726-34 [1326640.001]
  • [Cites] Virology. 1992 Nov;191(1):72-80 [1329338.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):163-73 [8321744.001]
  • [Cites] Virology. 1994 Jan;198(1):59-70 [8259683.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):994-7 [8057128.001]
  • [Cites] Hum Pathol. 1994 Dec;25(12):1341-5 [8001929.001]
  • [Cites] Acta Neuropathol. 1994;88(5):465-71 [7847076.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1590-7 [7882370.001]
  • [Cites] J Virol. 1996 Feb;70(2):1317-22 [8551602.001]
  • [Cites] Virology. 1996 Feb 1;216(1):90-101 [8615010.001]
  • [Cites] J Virol. 1998 Jun;72(6):4643-9 [9573227.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Mar;57(3):226-30 [9600214.001]
  • [Cites] J Neurol. 1998 Aug;245(8):557-8 [9747922.001]
  • [Cites] Cell. 1998 Oct 2;95(1):1-4 [9778239.001]
  • [Cites] Cell. 1998 Oct 2;95(1):41-53 [9778246.001]
  • [Cites] Cell. 1998 Oct 2;95(1):55-66 [9778247.001]
  • [Cites] J Virol. 1998 Dec;72(12):9918-23 [9811728.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):39-46 [9926918.001]
  • [Cites] J Med Virol. 1999 May;58(1):79-86 [10223551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7484-9 [10377441.001]
  • [Cites] Hum Mol Genet. 1999 Sep;8(9):1657-64 [10441328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11519-24 [10500209.001]
  • [Cites] Brain. 1958 Mar;81(1):93-111 [13523006.001]
  • [Cites] Science. 1965 Jun 11;148(3676):1477-9 [14301897.001]
  • [Cites] Lancet. 1959 Oct 10;2(7102):524-9 [13808583.001]
  • [Cites] Science. 2004 Nov 19;306(5700):1380-3 [15550673.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):516-27 [15630684.001]
  • [Cites] Clin Infect Dis. 2005 Mar 1;40(5):738-44 [15714422.001]
  • [Cites] Transpl Int. 2005 Jan;17(11):658-65 [15616809.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):847-54 [15731002.001]
  • [Cites] Ann Neurol. 2005 Apr;57(4):576-80 [15786466.001]
  • [Cites] J Infect Dis. 1973 Apr;127(4):467-70 [4571704.001]
  • [Cites] Science. 1973 Aug 17;181(4100):674-6 [4353360.001]
  • [Cites] Science. 1978 Sep 29;201(4362):1246-9 [211583.001]
  • [Cites] Acta Neuropathol. 1980;49(2):133-43 [6243841.001]
  • [Cites] Acta Pathol Jpn. 1981 Nov;31(6):953-61 [6274138.001]
  • [Cites] J Virol. 1984 Aug;51(2):458-69 [6086957.001]
  • [Cites] Am J Pathol. 1984 Sep;116(3):455-63 [6089567.001]
  • [Cites] Science. 1984 Dec 14;226(4680):1337-9 [6095453.001]
  • [Cites] Virus Res. 1987 Apr;7(2):159-68 [3035817.001]
  • [Cites] N Engl J Med. 1988 Feb 4;318(5):301-5 [2827029.001]
  • [Cites] J Virol. 1990 Jun;64(6):3139-43 [2159570.001]
  • [Cites] J Infect Dis. 1990 Jun;161(6):1128-33 [2161040.001]
  • [Cites] J Virol. 1991 May;65(5):2422-8 [1850021.001]
  • [Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]
  • [Cites] Cell. 1991 Aug 23;66(4):675-84 [1652369.001]
  • [Cites] Nature. 1991 Nov 28;354(6351):278-84 [1659663.001]
  • [Cites] Science. 1991 Nov 29;254(5036):1371-4 [1720570.001]
  • [Cites] Hum Pathol. 1992 May;23(5):581-6 [1568753.001]
  • [Cites] Nature. 1997 Oct 30;389(6654):971-4 [9353120.001]
  • [Cites] J Infect Dis. 1997 Dec;176(6):1603-9 [9395374.001]
  • [Cites] Glia. 1998 Apr;22(4):415-20 [9517574.001]
  • [Cites] J Neurovirol. 1998 Feb;4(1):59-68 [9531012.001]
  • [Cites] Neuropathology. 2001 Jun;21(2):129-37 [11396678.001]
  • [Cites] Virology. 2001 Jul 20;286(1):100-12 [11448163.001]
  • [Cites] J Neurovirol. 2001 Aug;7(4):345-9 [11517414.001]
  • [Cites] AIDS. 2001 Sep 28;15(14):1900-2 [11579261.001]
  • [Cites] J Virol. 2001 Nov;75(21):10290-9 [11581397.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7234-42 [11704851.001]
  • [Cites] Neuropediatrics. 2001 Oct;32(5):250-5 [11748496.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1486-8 [11830505.001]
  • [Cites] Cell. 2002 Jan 25;108(2):165-70 [11832207.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):267-73 [11854388.001]
  • [Cites] Neurology. 2002 Mar 26;58(6):895-900 [11914404.001]
  • [Cites] Neuroradiology. 2002 Mar;44(3):227-9 [11942377.001]
  • [Cites] Virology. 2002 Mar 30;295(1):97-107 [12033769.001]
  • [Cites] Brain. 2002 Jul;125(Pt 7):1534-43 [12077003.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):165-70 [12084346.001]
  • [Cites] J Virol. 2002 Oct;76(19):10009-14 [12208977.001]
  • [Cites] J Infect Dis. 2002 Dec 1;186 Suppl 2:S180-6 [12424695.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7093-101 [12460931.001]
  • [Cites] Arch Neurol. 2002 Dec;59(12):1930-6 [12470182.001]
  • [Cites] J Neurovirol. 2003 Apr;9(2):236-46 [12707854.001]
  • [Cites] J Neurovirol. 2003;9 Suppl 1:73-80 [12709876.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 May;62(5):429-40 [12769183.001]
  • [Cites] Cancer Sci. 2007 Jan;98(1):25-31 [17083566.001]
  • [Cites] J Pathol. 2007 Jul;212(3):306-15 [17534844.001]
  • [Cites] Biochimie. 2007 Jun-Jul;89(6-7):819-30 [17343971.001]
  • [Cites] Arthritis Rheum. 2007 Jul;56(7):2116-28 [17599729.001]
  • [Cites] J Neurovirol. 2007 Oct;13(5):474-6 [17994433.001]
  • [Cites] Curr Neurol Neurosci Rep. 2007 Nov;7(6):461-9 [17999891.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Dec;8(12):1006-16 [17928811.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):394-400 [18091381.001]
  • [Cites] J Autoimmun. 2008 Feb-Mar;30(1-2):90-8 [18191544.001]
  • [Cites] Neurology. 2008 Jan 29;70(5):336-43 [17914063.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Apr;67(4):299-308 [18379438.001]
  • [Cites] Lupus. 2008 Nov;17(11):1036-41 [18852230.001]
  • [Cites] Biochim Biophys Acta. 2008 Nov;1783(11):2207-21 [18775455.001]
  • [Cites] Ann Neurol. 2008 Oct;64(4):379-87 [18688812.001]
  • [Cites] Autoimmun Rev. 2008 Dec;8(2):144-6 [18700172.001]
  • [Cites] J Med Virol. 2008 Dec;80(12):2147-52 [19040292.001]
  • [Cites] J Neuropathol Exp Neurol. 2009 Jan;68(1):15-25 [19104450.001]
  • [Cites] J Infect Dis. 2009 Mar 15;199(6):881-8 [19434914.001]
  • [Cites] Int J Biol Sci. 2009;5(4):366-76 [19471587.001]
  • [Cites] Ann Neurol. 2009 Jun;65(6):742-8 [19557867.001]
  • (PMID = 20464404.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2910879
  •  go-up   go-down


26. Kröger L, Majuri S, Tyrväinen E, Jääskeläinen J: [Loss of mobility in a child with Down syndrome]. Duodecim; 2009;125(24):2739-42
MedlinePlus Health Information. consumer health - Juvenile Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Screening and monitoring of congenital heart defects or orthopedic problems are managed and the increased risk to develop leukemia, diabetes of hypothyroidism is well known.
  • The 3 to 6-fold incidence of juvenile idiopathic arthritis in Down syndrome compared with the general juvenile population is, however, less known.
  • We describe a patient, for whom the diagnostic delay of juvenile idiopathic arthritis was eight years.
  • [MeSH-major] Arthritis, Juvenile / etiology. Down Syndrome / complications

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175328.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Finland
  •  go-up   go-down


27. Oohashi E, Yamada K, Oohashi M, Ueda J: Chronic progressive polyarthritis in a female cat. J Vet Med Sci; 2010 Apr;72(4):511-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both feline leukemia virus antigen and feline immunodeficiency virus antibody were positive.

  • MedlinePlus Health Information. consumer health - Arthritis.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009422.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


28. Yang HP, Dai M, Zhang DH: [Progress of study on suppressor of cytokine signaling-1 - review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):437-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It plays an important role in the development of leukemia, rheumatoid arthritis, liver cirrhosis and liver cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493365.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Intracellular Signaling Peptides and Proteins; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor; 0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling Proteins
  • [Number-of-references] 22
  •  go-up   go-down


29. Kumana CR: Aspects of general medicine. Hong Kong Med J; 2008 Oct;14(5):385-90
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chapters summarised include: Contemporary management of acute myocardial infarction; Imported infectious disease emergencies; New therapies in the management of type 2 diabetes; Stress and adrenal insufficiency; Making sense of a 'funny thyroid function test'; Myeloproliferative disorders: management and molecular pathogenesis; Drug allergies; Osteoporosis; Rheumatoid arthritis; Understanding migraine from bench to bedside.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840910.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 2
  •  go-up   go-down


30. Moghadam A, Talebi-Taher M, Dehghan A: Sacroiliitis as an initial presentation of acute lymphoblastic leukaemia. Acta Clin Belg; 2010 May-Jun;65(3):197-9
MedlinePlus Health Information. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Arthritis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Sacroiliac Joint

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669789.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


31. Dennis G, Chitkara P: A case of human T lymphotropic virus type I-associated synovial swelling. Nat Clin Pract Rheumatol; 2007 Nov;3(11):675-80
MedlinePlus Health Information. consumer health - Infectious Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HTLV-I is the causative agent of adult T cell leukemia/lymphoma and is associated with myelopathy/tropical spastic paraparesis, uveitis, polymyositis, synovitis, thyroiditis, and bronchoalveolar pneumonia.
  • [MeSH-major] Arthritis, Infectious / etiology. Leukemia-Lymphoma, Adult T-Cell / complications. Synovitis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968339.001).
  • [ISSN] 1745-8390
  • [Journal-full-title] Nature clinical practice. Rheumatology
  • [ISO-abbreviation] Nat Clin Pract Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


32. Cwiklińska M, Balwierz W: [Osteoarticular pains as early manifestation of malignancies in children]. Przegl Lek; 2009;66(1-2):39-44
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteoarticular pains as early manifestation of malignancies in children].
  • When these complaints predominate in the clinical presentation, they lead the diagnosis towards nonmalignant conditions, that are most common cause of such symptoms in children, like injuries, nonspecific reactive arthritis or inflammatory connective tissue diseases.
  • [MeSH-major] Arthralgia / etiology. Arthritis / etiology. Neoplasms / complications. Neoplasms / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Fever / etiology. Hepatomegaly / etiology. Humans. Infant. Male. Retrospective Studies. Spinal Cord Compression / etiology. Splenomegaly / etiology. Weight Loss

  • MedlinePlus Health Information. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19485254.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


33. Robazzi TC, Barreto JH, Silva LR, Santiago MB, Mendonça N: Osteoarticular manifestations as initial presentation of acute leukemias in children and adolescents in Bahia, Brazil. J Pediatr Hematol Oncol; 2007 Sep;29(9):622-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Acute lymphocytic leukemia (ALL) was diagnosed in 313 (77.1%) patients and acute myeloid leukemia (AML), in 93 (22.9%) patients, including 241 males (59.4%) and 165 females (40.6%).
  • Prior referral to our center, the most frequent initial diagnosis was anemia (15.8%), leukemia (15.0%), amygdalitis (3.7%), and rheumatic fever (2.7%).
  • The presence of joint tenderness (16.2% in ALLx5.4% in AML), arthritis (26.6% in ALLx9.7 in AML), bone tenderness (26.1% in ALLx16.1% in AML), limb tenderness (49.5% in ALLx25.8% in AML), and antalgic gait (32.8% in ALLx9.7% in AML) had higher prevalence on ALL.
  • CONCLUSIONS: AL should be considered on the differential diagnosis of osteoarticular symptoms of unknown etiology in children.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Osteoarthritis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Osteoarthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805037.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O: Chronic immune stimulation and subsequent Waldenström macroglobulinemia. Arch Intern Med; 2008 Sep 22;168(17):1903-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These findings provide novel insights into the still unknown etiology of WM.
  • [MeSH-major] Autoimmune Diseases / complications. Waldenstrom Macroglobulinemia / etiology. Waldenstrom Macroglobulinemia / immunology


35. Biswas S, Keddington J, McClanathan J: Large B-cell lymphoma presenting as acute abdominal pain and spontaneous splenic rupture; a case report and review of relevant literature. World J Emerg Surg; 2006;1:35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute leukemia and non Hodgkin lymphoma were the frequent causes followed by chronic myelogenous leukemia.
  • We present a case report of a "spontaneous splenic rupture" and discuss the presentation, etiology and treatment options along with discussion of relevant literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 May;83(5):632 [8689204.001]
  • [Cites] Pathology. 1994 Oct;26(4):493-6 [7892057.001]
  • [Cites] AJR Am J Roentgenol. 1995 Mar;164(3):631-5 [7863884.001]
  • [Cites] Cancer. 1981 Dec 15;48(12):2729-33 [7306928.001]
  • [Cites] Am J Clin Pathol. 1984 Jul;82(1):104-9 [6234792.001]
  • [Cites] Mich Med. 1966 Feb;65(2):105-10 [5901949.001]
  • [Cites] Arch Surg. 1972 May;104(5):652-7 [4503094.001]
  • [Cites] Am J Emerg Med. 1989 Jan;7(1):28-31 [2643958.001]
  • [Cites] Acta Haematol. 2005;113(4):255-7 [15983432.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):131-5 [14508801.001]
  • [Cites] Int Abstr Surg. 1958 Jan;106(1):1-11 [13495867.001]
  • [Cites] Lupus. 2001;10(12):876-8 [11787878.001]
  • [Cites] J Pediatr Surg. 1999 Mar;34(3):498-9 [10211667.001]
  • [Cites] Eur J Surg. 1999 Jul;165(7):712-3 [10452269.001]
  • [Cites] Ann Hematol. 2000 Mar;79(3):158-60 [10803939.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8 [11298158.001]
  • [Cites] Clin Infect Dis. 1993 Feb;16(2):223-32 [8443301.001]
  • [Cites] Radiographics. 1994 Mar;14(2):307-32 [8190956.001]
  • [Cites] Ann Hematol. 1996 Dec;73(6):297-302 [9003161.001]
  • [Cites] Clin Infect Dis. 1997 Aug;25(2):336-7 [9332543.001]
  • [Cites] Semin Arthritis Rheum. 1997 Dec;27(3):141-55 [9431585.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):276-8 [9934775.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):89-93 [9022775.001]
  • (PMID = 17129392.001).
  • [ISSN] 1749-7922
  • [Journal-full-title] World journal of emergency surgery : WJES
  • [ISO-abbreviation] World J Emerg Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1712221
  •  go-up   go-down


36. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED: CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood; 2009 Feb 12;113(7):1581-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Organ-specific immune adverse events (IAE) were seen in 4 patients (grade 3 arthritis, grade 2 hyperthyroidism, recurrent grade 4 pneumonitis).

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Res. 1996;84:279-90 [8724634.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6368-77 [10352249.001]
  • [Cites] Oncologist. 2007 Jul;12(7):864-72 [17673617.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):741-50 [15613700.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6043-53 [16087944.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1005-16 [16283570.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2283-9 [16710025.001]
  • [Cites] Adv Immunol. 2006;90:297-339 [16730267.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):958-64 [17289891.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1810-5 [17363537.001]
  • [Cites] J Immunother. 2007 Nov-Dec;30(8):825-30 [18049334.001]
  • [Cites] Cancer Invest. 2007 Oct;25(7):613-31 [18027152.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8 [17982122.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2744-8 [17595333.001]
  • [Cites] Front Biosci. 2007;12:4568-94 [17485398.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1451-9 [17508005.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] Immunity. 1995 Nov;3(5):541-7 [7584144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Annu Rev Immunol. 2001;19:225-52 [11244036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 [18287062.001]
  • [Cites] Cancer Immun. 2008;8:1 [18198818.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • (PMID = 18974373.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00060372
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 9389-01A1
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / ipilimumab
  • [Other-IDs] NLM/ PMC2644086
  •  go-up   go-down


37. Gao Y, Kristinsson SY, Goldin LR, Björkholm M, Caporaso NE, Landgren O: Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology; 2009 Jan;136(1):91-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We identified 37,869 NHL, 8323 Hodgkin lymphoma (HL), and 13,842 chronic lymphocytic leukemia patients diagnosed in Sweden between 1965 and 2004, as well as 236,408 matched controls and 613,961 first-degree relatives.
  • Risk of HL was borderline increased (OR=2.54, 95% CI, 0.99-6.56); however, there was no excess chronic lymphocytic leukemia risk.
  • [MeSH-major] Celiac Disease / complications. Celiac Disease / genetics. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Male. Middle Aged. Risk


38. Groom J, Mackay F: B cells flying solo. Immunol Cell Biol; 2008 Jan;86(1):40-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Arthritis, Rheumatoid / immunology. Autoantibodies / biosynthesis. Autoantibodies / genetics. Autoantibodies / immunology. Autoantibodies / metabolism. Cell Survival / genetics. Cell Survival / immunology. Clonal Deletion / genetics. Clonal Deletion / immunology. Humans. Immunity, Innate / genetics. Immunity, Innate / immunology. Leukemia, B-Cell / etiology. Mice. Models, Biological. Self Tolerance / genetics. Self Tolerance / immunology. Sjogren's Syndrome / immunology

  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172443.001).
  • [ISSN] 0818-9641
  • [Journal-full-title] Immunology and cell biology
  • [ISO-abbreviation] Immunol. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / B-Cell Activating Factor
  • [Number-of-references] 105
  •  go-up   go-down


39. Kong YC, Wei WZ, Tomer Y: Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci; 2010 Jan;1183:222-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.
  • Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response.
  • Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials.
  • This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities:.
  • (1) systemic immunomodulators, including interferon-alpha (also used to treat hepatitis C patients) and interferon-beta;.
  • (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation.
  • Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants.
  • Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently.
  • Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2008 Jul 12;372(9633):89-90 [18620932.001]
  • [Cites] Ann Rheum Dis. 2008 Sep;67(9):1322-7 [18055469.001]
  • [Cites] Autoimmun Rev. 2008 Sep;7(8):631-7 [18774118.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(3):735-6 [18547306.001]
  • [Cites] Science. 2008 Oct 10;322(5899):271-5 [18845758.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Nov;110(9):878-85 [18164542.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1786-801 [18946064.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1838-41 [18946071.001]
  • [Cites] Eur J Endocrinol. 1995 May;132(5):587-93 [7749499.001]
  • [Cites] Science. 1995 Nov 10;270(5238):985-8 [7481803.001]
  • [Cites] Immunity. 1995 Nov;3(5):541-7 [7584144.001]
  • [Cites] Toxicology. 1995 Dec 20;105(1):31-57 [8638283.001]
  • [Cites] Clin Exp Immunol. 1996 Sep;105(3):523-8 [8809144.001]
  • [Cites] J Hepatol. 1996 Jan;24(1):38-47 [8834023.001]
  • [Cites] J Hepatol. 1996 Sep;25(3):283-91 [8895006.001]
  • [Cites] Am J Med. 1996 Nov;101(5):482-7 [8948271.001]
  • [Cites] J Clin Invest. 1996 Dec 15;98(12):2819-26 [8981930.001]
  • [Cites] Clin Exp Immunol. 1997 Feb;107(2):359-63 [9030876.001]
  • [Cites] Clin Immunol Immunopathol. 1997 Sep;84(3):223-43 [9281381.001]
  • [Cites] Thyroid. 1997 Dec;7(6):891-6 [9459633.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1998 Feb;30(1):71-6 [9615270.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2489-99 [9635566.001]
  • [Cites] QJM. 1998 Jun;91(6):393-9 [9709457.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:16-25 [19001147.001]
  • [Cites] J Autoimmun. 2008 Nov;31(3):219-27 [18501558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] J Immunol. 2009 May 1;182(9):5873-81 [19380836.001]
  • [Cites] J Autoimmun. 2009 Aug;33(1):68-76 [19375891.001]
  • [Cites] Autoimmun Rev. 2009 Sep;9(1):28-33 [19254781.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1167-72 [9064334.001]
  • [Cites] Lancet. 1999 Nov 13;354(9191):1691-5 [10568572.001]
  • [Cites] Immunol Today. 2000 Oct;21(10):484-9 [11071526.001]
  • [Cites] J Interferon Cytokine Res. 2000 Dec;20(12):1039-47 [11152569.001]
  • [Cites] Oncologist. 2001;6(1):34-55 [11161227.001]
  • [Cites] Neuro Endocrinol Lett. 2001;22(1):49-52 [11335880.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1925-9 [11344186.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3525-32 [11502774.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Chin Med J (Engl). 1999 Jan;112(1):61-6 [11593644.001]
  • [Cites] Bone Marrow Transplant. 2001 Dec;28(12):1151-3 [11803358.001]
  • [Cites] J Intern Med. 2002 May;251(5):400-6 [11982739.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jun;56(6):793-8 [12072050.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2063-6 [12242445.001]
  • [Cites] J Intern Med. 2002 Oct;252(4):377-8; author reply 379 [12366611.001]
  • [Cites] J Clin Immunol. 2003 Jan;23(1):62-72 [12645861.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3522-7 [12646613.001]
  • [Cites] Gastroenterology. 2003 May;124(6):1711-9 [12761728.001]
  • [Cites] Am J Transplant. 2006 May;6(5 Pt 1):1084-5 [16611348.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Jun;18(6):693-4 [16702862.001]
  • [Cites] Nature. 2003 May 29;423(6939):506-11 [12724780.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):89-95 [12815483.001]
  • [Cites] Thyroid. 2003 Jun;13(6):547-51 [12930598.001]
  • [Cites] Curr Opin Oncol. 2003 Nov;15(6):431-9 [14624225.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):20-9 [14746804.001]
  • [Cites] Clin Dev Immunol. 2003 Jun-Dec;10(2-4):161-5 [14768947.001]
  • [Cites] Leukemia. 2004 Mar;18(3):484-90 [14749699.001]
  • [Cites] Autoimmunity. 2003 Dec;36(8):511-8 [14984028.001]
  • [Cites] Clin Exp Med. 2004 Apr;3(4):199-210 [15103510.001]
  • [Cites] Endocrinology. 2004 Aug;145(8):3724-30 [15117875.001]
  • [Cites] Pathol Annu. 1978;13 Pt 2:399-413 [581904.001]
  • [Cites] Lancet. 1985 May 18;1(8438):1166 [2860373.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Nov;63(5):1086-90 [2944910.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Aug;24(8):1299-303 [2460358.001]
  • [Cites] Clin Exp Immunol. 1990 Jul;81(1):72-5 [2199098.001]
  • [Cites] Ann Hematol. 1991 Feb;62(1):25-31 [1903309.001]
  • [Cites] Ann Intern Med. 1991 Aug 1;115(3):178-83 [2058872.001]
  • [Cites] JAMA. 1991 Sep 11;266(10):1375-83 [1715409.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):2155-60 [1587439.001]
  • [Cites] Am J Med. 1992 Jun;92(6):693-7 [1605152.001]
  • [Cites] J Immunol. 1992 Aug 1;149(3):1086-92 [1634763.001]
  • [Cites] Am J Gastroenterol. 1994 Mar;89(3):399-403 [8122653.001]
  • [Cites] Haematologica. 1994 Jul-Aug;79(4):367-70 [7806093.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):922-6 [7883851.001]
  • [Cites] Acta Haematol. 1995;93(1):31-5 [7725847.001]
  • [Cites] J Endocrinol Invest. 1998 Dec;21(11):748-52 [9972674.001]
  • [Cites] J Hepatol. 1999 May;30(5):794-800 [10365804.001]
  • [Cites] Eur J Endocrinol. 1999 Oct;141(4):325-31 [10526243.001]
  • [Cites] Am J Transplant. 2005 Mar;5(3):465-74 [15707400.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2499-506 [15728455.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):805-16 [15738052.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 2):874-86 [15760415.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7433-9 [15905592.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):412-9 [16000961.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4133-7 [15811929.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4138-44 [15855253.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8471-8 [16166327.001]
  • [Cites] J Immunother. 2005 Nov-Dec;28(6):593-8 [16224277.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7746-54 [16301685.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1005-16 [16283570.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8968-77 [16204013.001]
  • [Cites] Front Biosci. 2006;11:1234-43 [16368509.001]
  • [Cites] J Neurol. 2006 Jan;253(1):98-108 [16044212.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] Hepatology. 2006 Apr;43(4):661-72 [16557537.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2283-9 [16710025.001]
  • [Cites] Clin Immunol. 2006 Sep;120(3):247-59 [16797237.001]
  • [Cites] Clin Immunol. 2006 Oct;121(1):108-17 [16916620.001]
  • [Cites] Curr Opin Immunol. 2006 Dec;18(6):710-7 [17011768.001]
  • [Cites] J Clin Immunol. 2007 Jan;27(1):1-18 [17216565.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2643-548 [17119125.001]
  • [Cites] Haematologica. 2007 Apr;92(4):533-41 [17488664.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3644-53 [17530018.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):7020-7 [17638915.001]
  • [Cites] Oncologist. 2007 Jul;12(7):873-83 [17673618.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2562-6 [17680564.001]
  • [Cites] Endocrinol Metab Clin North Am. 2007 Dec;36(4):1051-66; x-xi [17983936.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8 [17982122.001]
  • [Cites] Autoimmun Rev. 2008 Jan;7(3):198-203 [18190878.001]
  • [Cites] J Autoimmun. 2008 May;30(3):116-20 [18242956.001]
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):370-5 [18240243.001]
  • [Cites] J Clin Rheumatol. 2008 Jun;14(3):166-8 [18525437.001]
  • (PMID = 20146718.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK073681; United States / NCI NIH HHS / CA / CA125680; United States / NIDDK NIH HHS / DK / DK45960; United States / NIDDK NIH HHS / DK / R01 DK045960; United States / NCI NIH HHS / CA / R01 CA125680; United States / NIDDK NIH HHS / DK / DK61659; United States / NCI NIH HHS / CA / P30 CA022453; United States / NIDDK NIH HHS / DK / R01 DK061659; United States / NIDDK NIH HHS / DK / DK073681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunologic Factors
  • [Number-of-references] 116
  • [Other-IDs] NLM/ NIHMS513225; NLM/ PMC3815555
  •  go-up   go-down


40. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum; 2010 Aug;62(8):2517-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The remaining reported cases involved a variety of different malignancies including leukemia, melanoma, and solid organ cancers.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Arthritis, Juvenile / therapy. Immunoglobulin G / adverse effects. Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2010 Aug;62(8):2183-4 [20506203.001]
  • (PMID = 20506368.001).
  • [ISSN] 1529-0131
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


41. Pneumaticos SG, Chatziioannou SN, Savvidou C, Pilichou A, Rontogianni D, Korres DS: Routine needle biopsy during vertebral augmentation procedures. Is it necessary? Eur Spine J; 2010 Nov;19(11):1894-8
MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to determine the frequency of underlying previously unrecognized etiology in a consecutive series of patients undergoing kyphoplasty to treat vertebral compression fractures.
  • In 11 patients underlying pathology other than osteoporosis was identified (prostate cancer, 1; pancreatic cancer, 1; colon cancer, 1; breast cancer, 2; multiple myeloma, 3; leukemia, 1; and lung cancer, 2).
  • In augmentation procedures for vertebral compression fractures, bone biopsy should be reserved for the patients where the preoperative evaluation raises the suspicion of a non-osteoporotic etiology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone. 1992;13 Suppl 2:S27-31 [1627411.001]
  • [Cites] Am Rev Respir Dis. 1990 Jan;141(1):68-71 [2297189.001]
  • [Cites] Bone. 1994 Jan-Feb;15(1):27-30 [8024847.001]
  • [Cites] Bone. 1995 Nov;17(5 Suppl):505S-511S [8573428.001]
  • [Cites] Bone. 1996 Mar;18(3 Suppl):185S-189S [8777086.001]
  • [Cites] Radiol Clin North Am. 1998 May;36(3):533-46 [9597071.001]
  • [Cites] Osteoporos Int. 1998;8(3):261-7 [9797911.001]
  • [Cites] Arch Intern Med. 1999 Jun 14;159(11):1215-20 [10371229.001]
  • [Cites] Spine (Phila Pa 1976). 2005 Apr 1;30(7):781-6 [15803081.001]
  • [Cites] J Bone Joint Surg Am. 2006 Dec;88(12):2721-4 [17142423.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Apr 15;25(8):923-8 [10767803.001]
  • [Cites] Spine (Phila Pa 1976). 2000 May 1;25(9):1051-2 [10788846.001]
  • [Cites] Eur Spine J. 2000 Oct;9(5):445-50 [11057541.001]
  • [Cites] Spine (Phila Pa 1976). 2001 Jul 15;26(14):1511-5 [11462078.001]
  • [Cites] Clin Imaging. 2002 Jan-Feb;26(1):1-5 [11814744.001]
  • [Cites] J Vasc Interv Radiol. 2002 Feb;13(2 Pt 1):137-8 [11830618.001]
  • [Cites] Neuroradiology. 2002 Nov;44(11):950-4 [12428134.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1 Suppl):36-42 [12546386.001]
  • [Cites] Radiology. 2003 Jun;227(3):662-8 [12702821.001]
  • [Cites] Orthopade. 2004 Jan;33(1):22-30 [14747907.001]
  • [Cites] Eur Spine J. 2004 May;13(3):184-92 [14986073.001]
  • [Cites] Spine (Phila Pa 1976). 2004 Oct 1;29(19):2120-5 [15454702.001]
  • [Cites] Neurochirurgie. 1987;33(2):166-8 [3600949.001]
  • [Cites] Arthritis Rheum. 1993 Jun;36(6):750-6 [8507215.001]
  • (PMID = 20372942.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2989251
  •  go-up   go-down


42. Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O: Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst; 2010 Apr 21;102(8):557-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.
  • BACKGROUND: Chronic immune stimulation appears to be associated with lymphoplasmacytic lymphoma (LPL)-Waldenström macroglobulinemia (WM); however, available information is sparse.
  • We conducted, to our knowledge, the most comprehensive study to date to evaluate associations between a personal or family history of many immune-related and/or inflammatory disorders and the subsequent risk of LPL-WM.
  • METHODS: We used Swedish population-based registries to identify 2470 case patients with LPL-WM, 9698 matched control subjects, and almost 30 000 first-degree relatives of either case patients or control subjects.
  • We evaluated a wide range of autoimmune, infectious, allergic, and inflammatory conditions.
  • We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for each condition by use of logistic regression.
  • RESULTS: An increased risk of LPL-WM was associated with a personal history of the following autoimmune diseases: systemic sclerosis (OR = 4.7, 95% CI = 1.4 to 15.3), Sjögren syndrome (OR = 12.1, 95% CI = 3.3 to 45.0), autoimmune hemolytic anemia (OR = 24.2, 95% CI = 5.4 to 108.2), polymyalgia rheumatica (OR = 2.9, 95% CI = 1.6 to 5.2), and giant cell arteritis (OR = 8.3, 95% CI = 2.1 to 33.1).
  • An increased risk of LPL-WM was associated with a personal history of the following infectious diseases: pneumonia (OR = 1.4, 95% CI = 1.1 to 1.7), septicemia (OR = 2.4, 95% CI = 1.2 to 4.3), pyelonephritis (OR = 1.7, 95% CI = 1.1 to 2.5), sinusitis (OR = 2.7, 95% CI = 1.4 to 4.9), herpes zoster (OR = 3.4, 95% CI = 2.0 to 5.6), and influenza (OR = 2.9, 95% CI = 1.7 to 5.0).
  • An increased risk of LPL-WM was associated with a family history of the following autoimmune or infectious diseases: Sjögren syndrome (OR = 5.0, 95% CI = 2.1 to 12.0), autoimmune hemolytic anemia (OR = 3.8, 95% CI = 1.1 to 13.2), Guillain-Barré syndrome (OR = 4.1, 95% CI = 1.8 to 9.4), cytomegalovirus (OR = 2.7, 95% CI = 1.4 to 5.3), gingivitis and periodontitis (OR = 1.9, 95% CI = 1.3 to 2.7), and chronic prostatitis (OR = 4.3, 95% CI = 1.7 to 11.1).
  • CONCLUSIONS: Personal history of certain immune-related and/or infectious conditions was strongly associated with increased risk of LPL-WM.
  • The association of both personal and family history of Sjögren syndrome and autoimmune hemolytic anemia with risk of LPL-WM indicates the potential for shared susceptibility for these conditions.

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jan;18(1):214-26 [10623712.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1497-502 [19089924.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • [Cites] Acta Med Scand. 1982 May;211(3):237-9 [6805257.001]
  • [Cites] Leukemia. 1993 Sep;7(9):1363-9 [8371587.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3148-50 [8219203.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3647-53 [8204889.001]
  • [Cites] Scand J Immunol. 1994 Aug;40(2):195-200 [8047841.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1913-9 [7703494.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1078-81 [9506352.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):488-94 [16357024.001]
  • [Cites] Am J Hum Genet. 2006 Oct;79(4):695-701 [16960805.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1697-700 [17145609.001]
  • [Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]
  • [Cites] Haematologica. 2007 May;92(5):635-42 [17488687.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5063-9 [17785558.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2260-6 [17583571.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):825-40 [17908622.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):717-23 [18021086.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1885-90 [18271005.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3388-94 [18239085.001]
  • [Cites] Arch Intern Med. 2008 Sep 22;168(17):1903-9 [18809818.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3052-6 [18703425.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):963-70 [12687538.001]
  • (PMID = 20181958.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2857799
  •  go-up   go-down


43. Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N: Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis; 2006 Sep;65(9):1184-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Lymphoma / etiology. Spondylitis, Ankylosing / complications
  • [MeSH-minor] Adult. Aged. Epidemiologic Methods. Female. Hospitalization / statistics & numerical data. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Sweden / epidemiology


44. Gonçalves M, Terreri MT, Barbosa CM, Len CA, Lee L, Hilário MO: Diagnosis of malignancies in children with musculoskeletal complaints. Sao Paulo Med J; 2005 Jan 2;123(1):21-3
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Musculoskeletal complaints may be associated with neoplasias as an initial manifestation of the disease.
  • The most common features presented were pauciarticular arthritis or arthralgia involving the large joints.
  • Juvenile rheumatoid arthritis was the most frequent initial diagnosis, in four out of nine patients.
  • The malignancies found included acute lymphocytic leukemia, acute myeloid leukemia, lymphoma, neuroblastoma and Ewing's sarcoma.
  • [MeSH-major] Musculoskeletal Diseases / etiology. Neoplasms / complications. Pain / etiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Sao Paulo Med J. 2005 Mar 2;123(2):49
  • (PMID = 15821811.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


45. Borm GF, Lemmers O, Fransen J, Donders R: The evidence provided by a single trial is less reliable than its statistical analysis suggests. J Clin Epidemiol; 2009 Jul;62(7):711-715.e1
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Data Interpretation, Statistical. Electromagnetic Fields / adverse effects. Humans. Leukemia, Radiation-Induced / epidemiology. Leukemia, Radiation-Induced / etiology. Outcome Assessment (Health Care) / methods. Patient Selection. Research Design

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Epidemiol. 2009 Aug;62(8):886-7; author reply 887-9 [19481419.001]
  • (PMID = 19171462.001).
  • [ISSN] 1878-5921
  • [Journal-full-title] Journal of clinical epidemiology
  • [ISO-abbreviation] J Clin Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  •  go-up   go-down


46. Poiraud C, Gagey-Caron V, Barbarot S, Durant C, Ayari S, Stalder JF: [Cutaneous, mucosal and systemic pyoderma gangrenosum]. Ann Dermatol Venereol; 2010 Mar;137(3):212-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 56-year-old man was hospitalised for an inflammatory abdominal plaque with an ulcerated centre that appeared rapidly in a setting of fever of 40 degrees C, odynophagia, weight loss and arthritis of the ankle.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Mouth Mucosa / pathology. Pyoderma Gangrenosum / pathology
  • [MeSH-minor] Fever / etiology. Humans. Male. Middle Aged. Mouth Diseases / etiology

  • Genetic Alliance. consumer health - Pyoderma gangrenosum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20227565.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


47. Said JW: Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol; 2007 May;14(3):189-94
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topics under review include: (a) CHL posttransplant lymphoproliferative disorders, (b) CHL in HIV/AIDS, (c) Hodgkin variant of Richter syndrome in chronic lymphocytic leukemia in association with fludarabine therapy, (d) CHL in other immunodeficiency states including methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis and primary immune deficiencies, and (e) Hodgkin-like lymphoid proliferations including senile Epstein-Barr virus+ B-cell lymphoproliferative disorder.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Hodgkin Disease / etiology. Hodgkin Disease / immunology. Hodgkin Disease / pathology. Immunologic Deficiency Syndromes / complications. Lymphoma, AIDS-Related / immunology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452815.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


48. Almoallim H, Patterson AC: Microscopic polyangiitis sparing the kidneys in a long-term survivor after allogeneic bone marrow transplantation and graft-versus-host disease. Clin Rheumatol; 2005 Aug;24(4):439-41
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / etiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Polyarteritis Nodosa / etiology


49. Ramakrishnan A, Deeg HJ: A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease. Expert Opin Biol Ther; 2009 Jan;9(1):21-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease.
  • BACKGROUND: The marrow microenvironment is composed of a complex network of cells and extra cellular matrix that cooperate to regulate normal hematopoiesis.
  • There is growing evidence that microenvironmental defects can contribute to the pathogenesis of hematological malignancies.
  • OBJECTIVE/METHODS: We review the role of the microenvironment in inducing and sustaining hematological malignancies.
  • RESULTS/CONCLUSIONS: Two basic mechanisms could explain the role of microenvironmental defects in the evolution of hematopoietic neoplasms.
  • There is significant data to support the first mechanism, in which the malignant hematopoietic clone induces reversible functional changes in the microenvironment that result in improved growth conditions for the malignant cells.
  • More recent studies from mouse models have indicated that a second mechanism involving primary microenvironmental defects can also result in malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 May 10;277(19):16639-47 [11872748.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):677-86 [12008086.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):687-8 [12008087.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1123-32 [12149188.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5673-83 [12173037.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3495-503 [12393681.001]
  • [Cites] Leuk Res. 2003 May;27(5):425-36 [12620294.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2983-9 [12506018.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):836-41 [14574412.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):841-6 [14574413.001]
  • [Cites] Blood. 2004 May 1;103(9):3258-64 [14726388.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1489-99 [17369076.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 1:S7 [17634146.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1937-44 [17611569.001]
  • [Cites] Exp Hematol. 2007 Nov;35(11):1739-46 [17976524.001]
  • [Cites] Int J Hematol. 2007 Nov;86(4):301-5 [18055335.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612 [18070708.001]
  • [Cites] Br J Haematol. 2008 Feb;140(4):444-53 [18162123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2865-70 [18287021.001]
  • [Cites] Leuk Res. 2008 Sep;32(9):1407-16 [18405968.001]
  • [Cites] Blood. 2008 Jul 1;112(1):196-207 [18305214.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):43503-8 [11571304.001]
  • [Cites] J Cell Physiol. 1977 Jun;91(3):335-44 [301143.001]
  • [Cites] Adv Genet. 1979;20:357-459 [390999.001]
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):405-14 [10752992.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1255-65 [10781623.001]
  • [Cites] Br J Haematol. 2000 Nov;111(2):626-34 [11122111.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4519-27 [11494147.001]
  • [Cites] Blood. 1965 Oct;26(4):399-410 [5317869.001]
  • [Cites] Radiology. 1970 Feb;94(2):441-5 [4904901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Aug;77(8):4756-9 [6933522.001]
  • [Cites] Blood. 1985 May;65(5):1172-4 [2986742.001]
  • [Cites] Exp Hematol. 1986 May;14(4):287-92 [3516716.001]
  • [Cites] Nature. 1987 Jul 30-Aug 5;328(6129):429-32 [2886914.001]
  • [Cites] Blood. 1987 Dec;70(6):1966-8 [3315046.001]
  • [Cites] J Clin Invest. 1988 Apr;81(4):1072-80 [3350965.001]
  • [Cites] Bone Marrow Transplant. 1989 Sep;4(5):581-5 [2790337.001]
  • [Cites] Cell. 1990 Oct 5;63(1):167-74 [1698553.001]
  • [Cites] Cell. 1990 Oct 5;63(1):175-83 [1698554.001]
  • [Cites] Cell. 1990 Oct 5;63(1):225-33 [1698557.001]
  • [Cites] Crit Rev Oncol Hematol. 1991;11(1):65-84 [1883527.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;177:123-36 [1379138.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2306-14 [1421401.001]
  • [Cites] Eur J Haematol. 1992 Nov;49(5):225-33 [1473584.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3712-20 [8260708.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S133-5 [8152280.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3636-45 [7780147.001]
  • [Cites] Ann Hematol. 1996 Aug;73(2):53-70 [8774614.001]
  • [Cites] Cell. 1997 Apr 18;89(2):309-19 [9108485.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4369-83 [9373248.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602 [9520411.001]
  • [Cites] Cell. 1998 Apr 17;93(2):165-76 [9568710.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):345-57 [10368775.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2631-9 [15585658.001]
  • [Cites] Blood. 2005 May 1;105(9):3493-501 [15665119.001]
  • [Cites] Immunity. 2005 Apr;22(4):479-91 [15845452.001]
  • [Cites] Clin Adv Hematol Oncol. 2005 Oct;3(10):799-819 [16258490.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):29-33 [16397211.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Leukemia. 2006 Jan;20(1):128-35 [16270037.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5495-503 [16707479.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(3):399-412 [16781480.001]
  • [Cites] Blood. 2006 Aug 1;108(3):836-46 [16597592.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(11):1564-73 [16765041.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55 [17067911.001]
  • [Cites] Blood. 2007 Jan 1;109(1):85-92 [16954500.001]
  • [Cites] Exp Hematol. 2007 Feb;35(2):221-9 [17258071.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):19-27 [17336251.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1081-95 [17574022.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1097-110 [17574023.001]
  • [Cites] Oncogene. 2001 Sep 20;20(42):5991-6000 [11593406.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):577-82 [11740812.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1950-61 [11753617.001]
  • [Cites] Leukemia. 2002 Feb;16(2):162-4 [11840280.001]
  • [Cites] Bone Marrow Transplant. 2002 Mar;29(5):453-6 [11919737.001]
  • (PMID = 19063690.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL082941; United States / NHLBI NIH HHS / HL / HL082941; United States / NHLBI NIH HHS / HL / R01 HL082941-04; United States / NHLBI NIH HHS / HL / P01 HL036444; United States / NHLBI NIH HHS / HL / P01 HL036444-30; United States / NHLBI NIH HHS / HL / HL082941-04; United States / NHLBI NIH HHS / HL / HL03644
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 90
  • [Other-IDs] NLM/ NIHMS214623; NLM/ PMC2911479
  •  go-up   go-down


50. Gu M, Wilton R, Stevens FJ: Diversity and diversification of light chains in myeloma: the specter of amyloidogenesis by proxy. Contrib Nephrol; 2007;153:156-81
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patterns of light chain germline gene usage in myeloma patients were compared to those found in other immune system disorders: lymphoma, leukemia, systemic lupus erythematosus and rheumatoid arthritis.
  • CONCLUSION: The plasma cell dyscrasias including myeloma, lymphoma, leukemia, and monoclonal gammopathy of undetermined significance are usually monoclonal diseases; however, the light chains produced are not homogeneous.
  • [MeSH-major] Amyloidosis / etiology. Immunoglobulin Light Chains / genetics. Multiple Myeloma / genetics. Multiple Myeloma / immunology

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075229.001).
  • [ISSN] 0302-5144
  • [Journal-full-title] Contributions to nephrology
  • [ISO-abbreviation] Contrib Nephrol
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG18001; United States / NIDDK NIH HHS / DK / DK43957
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 9007-49-2 / DNA
  • [Number-of-references] 150
  •  go-up   go-down


51. Karia VR, Cuchacovich R, Espinoza LR: Undifferentiated spondyloarthritis following allogeneic stem cell transplantation. BMC Musculoskelet Disord; 2010;11:132
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Arthritis, Rheumatoid / etiology. Cell Differentiation / physiology. Spondylitis, Ankylosing / etiology. Stem Cell Transplantation / adverse effects. Transplantation, Homologous / adverse effects
  • [MeSH-minor] Adult. Disease Progression. Humans. Leukemia, B-Cell / pathology. Leukemia, B-Cell / therapy. Male

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Ankylosing Spondylitis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(6):673-5 [11035374.001]
  • [Cites] Semin Arthritis Rheum. 2009 Aug;39(1):55-60 [18519150.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(6):641-6 [11319595.001]
  • [Cites] Bone Marrow Transplant. 2002 Oct;30(8):527-9 [12379893.001]
  • [Cites] Nephrol Dial Transplant. 2002 Dec;17(12):2280-1 [12454257.001]
  • [Cites] Bone Marrow Transplant. 1990 Nov;6(5):345-7 [2291997.001]
  • [Cites] Z Rheumatol. 1991 Jul-Aug;50(4):199-203 [1746167.001]
  • [Cites] Bone Marrow Transplant. 1998 May;21(9):966-7 [9613796.001]
  • [Cites] Rheumatology (Oxford). 1999 Jan;38(1):89-90 [10334690.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):349-60 [17448966.001]
  • [Cites] Arthritis Rheum. 2007 Jul;56(7):2410-21 [17599770.001]
  • [Cites] Rheumatol Int. 2007 Oct;27(12):1167-9 [17429637.001]
  • [Cites] Autoimmun Rev. 2008 Jan;7(3):198-203 [18190878.001]
  • [Cites] Arthritis Rheum. 2009 May;60(5):1311-6 [19404948.001]
  • [Cites] N Engl J Med. 2009 Jun 18;360(25):2645-54 [19535803.001]
  • [Cites] Ann Med. 2000 Dec;32(9):615-21 [11209969.001]
  • (PMID = 20579362.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2902413
  •  go-up   go-down


52. Koreny T, Tunyogi-Csapó M, Gál I, Vermes C, Jacobs JJ, Glant TT: The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum; 2006 Oct;54(10):3221-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most prominent up-regulated genes and proteins secreted by fibroblasts in response to stimulation were matrix metalloproteinase 1, MCP-1, IL-1beta, IL-6, IL-8, cyclooxygenase 1 (COX-1), COX-2, leukemia inhibitory factor 1, transforming growth factor beta1 (TGFbeta1), and TGFbeta receptor type I.
  • [MeSH-major] Arthroplasty, Replacement, Knee / adverse effects. Cytokines / metabolism. Fibroblasts / metabolism. Fibroblasts / pathology. Knee Prosthesis / adverse effects. Osteolysis / etiology. Osteolysis / metabolism

  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TITANIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009257.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / Osteoprotegerin; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / TNFSF11 protein, human; 0 / Vascular Endothelial Growth Factor A; 81627-83-0 / Macrophage Colony-Stimulating Factor; D1JT611TNE / Titanium
  •  go-up   go-down


53. Li Z, Wang H, Xue L, Shin DM, Roopenian D, Xu W, Qi CF, Sangster MY, Orihuela CJ, Tuomanen E, Rehg JE, Cui X, Zhang Q, Morse HC 3rd, Morris SW: Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma. Blood; 2009 Nov 5;114(19):4158-68
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.
  • BCL10, required for nuclear factor kappaB (NF-kappaB) activation during antigen-driven lymphocyte responses, is aberrantly expressed in mucosa-associated lymphoid tissue-type marginal zone (MZ) lymphomas because of chromosomal translocations.
  • Emu-driven human BCL10 transgenic (Tg) mice, which we created and characterize here, had expanded populations of MZ B cells and reduced follicular and B1a cells.
  • Splenic B cells from Tg mice exhibited constitutive activation of both canonical and noncanonical NF-kappaB signaling pathways is associated with increased expression of NF-kappaB target genes.
  • These genes included Tnfsf13b, which encodes the B-cell activating factor (BAFF).
  • In addition, levels of BAFF were significantly increased in sera from Tg mice.
  • MZ B cells of Tg mice exhibited reduced turnover in vivo and enhanced survival in vitro, indicative of lymphoaccumulation rather than lymphoproliferation as the cause of MZ expansion.
  • In vivo antibody responses to both T-independent, and especially T-dependent, antigens were significantly reduced in Tg mice.
  • Mortality was accelerated in Tg animals, and some mice older than 8 months had histologic and molecular findings indicative of clonal splenic MZ lymphoma.
  • These results suggest that, in addition to constitutive activation of BCL10 in MZ B cells, other genetic factors or environmental influences are required for short latency oncogenic transformation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2004 Jun;20(6):785-98 [15189742.001]
  • [Cites] Nat Rev Immunol. 2004 May;4(5):348-59 [15122200.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2247-53 [15251985.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2124-30 [8187765.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):805-12 [10079258.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12):7198-207 [10358166.001]
  • [Cites] Science. 1999 Jul 2;285(5424):113-6 [10390361.001]
  • [Cites] J Pathol. 2005 Feb;205(3):293-301 [15682443.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1037-41 [15845895.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2105-12 [15878976.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4210-6 [16123224.001]
  • [Cites] Gut. 2006 Jan;55(1):137-8 [16344587.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):1081-91 [16606676.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5270-7 [16707452.001]
  • [Cites] Immunity. 2006 Sep;25(3):403-15 [16973390.001]
  • [Cites] Nat Rev Immunol. 2006 Nov;6(11):799-812 [17063183.001]
  • [Cites] Immunity. 2006 Nov;25(5):701-15 [17098202.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1693-6 [17145608.001]
  • [Cites] Leukemia. 2007 Mar;21(3):389-96 [17230229.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2439-47 [17363561.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):327-36 [17433868.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):984-91 [17660823.001]
  • [Cites] J Immunol. 2007 Nov 1;179(9):5947-57 [17947668.001]
  • [Cites] J Clin Exp Hematop. 2007 Nov;47(2):31-42 [18040143.001]
  • [Cites] Eur J Immunol. 2007 Dec;37(12):3339-51 [18034429.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2927-34 [18628489.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9202-11 [19010892.001]
  • [Cites] Hematol Oncol. 2000 Mar;18(1):1-13 [10797525.001]
  • [Cites] J Exp Med. 2000 Oct 16;192(8):1175-82 [11034607.001]
  • [Cites] Cell. 2001 Jan 12;104(1):33-42 [11163238.001]
  • [Cites] Immunity. 2001 May;14(5):617-29 [11371363.001]
  • [Cites] Trends Immunol. 2001 Jul;22(7):356-60 [11429318.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):241-9 [11869899.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4514-9 [11930006.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4314-21 [12370363.001]
  • [Cites] J Exp Med. 2003 Jan 6;197(1):87-99 [12515816.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2335-9 [12406890.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):357-65 [12649336.001]
  • [Cites] Immunity. 2003 Jun;18(6):763-75 [12818158.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1719-27 [12840047.001]
  • [Cites] Immunol Rev. 2003 Aug;194:8-18 [12846803.001]
  • [Cites] Nat Immunol. 2003 Sep;4(9):857-65 [12910267.001]
  • [Cites] Immunity. 2003 Nov;19(5):749-58 [14614861.001]
  • [Cites] Science. 2003 Nov 28;302(5650):1581-4 [14576442.001]
  • [Cites] Arthritis Rheum. 2003 Dec;48(12):3475-86 [14673998.001]
  • [Cites] Blood. 2004 Jan 15;103(2):679-88 [14504101.001]
  • [Cites] Nature. 2004 Jan 8;427(6970):167-71 [14695475.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3860-73 [15082780.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):15-9 [15210753.001]
  • (PMID = 19696203.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R21 AG029313; United States / NCI NIH HHS / CA / CA21765; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA087064; United States / NCI NIH HHS / CA / R01 CA87064
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BCL10 protein, human; 0 / NF-kappa B; 0 / Recombinant Proteins
  • [Other-IDs] NLM/ PMC2774552
  •  go-up   go-down


54. Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, Call TG, Dogan A, Cunningham JM, Wang AH, Liu-Mares W, Macon WR, Jelinek D, Witzig TE, Habermann TM, Slager SL: Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood; 2007 Dec 15;110(13):4455-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results suggest that genetic variation in genes associated with immune response (TRAF1, RIPK3, BAT2, and TLR6), mitogen-activated protein kinase (MAPK) signaling (MAP3K5, DUSP2, and CREB1), lymphocyte trafficking and migration (B3GNT3, SELPLG, and LSP1), and coagulation pathways (FGG and ITGB3) may be important in the etiology of NHL, and should be prioritized in replication studies.


55. Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML: Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. Blood; 2010 Jun 3;115(22):4464-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation.
  • Familial aggregation of Waldenström macroglobulinemia (WM) and related B-cell disorders (BCDs) suggests a role for genetic factors, but few data address environmental influences.
  • We designed a questionnaire-based study to examine clinical and environmental factors in a cohort of WM families with various patterns of case aggregation.
  • We analyzed data on 103 WM patients and 272 unaffected relatives from 35 multiple-case WM and 46 mixed WM/BCD kindred and 28 nonfamilial (sporadic) WM patients, using logistic regression models with generalized estimating equations to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for association.
  • In this study population, the WM disease process appeared similar among patients regardless of family history.
  • Familial WM patients were more likely than unaffected relatives to report a history of autoimmune disease (OR, 2.27; 95% CI = 1.21-4.28) and infections (OR, 2.13; 95% CI = 1.25-3.64).
  • Familial WM patients were also more likely to report exposure to farming (OR, 2.70; 95% CI = 1.34-5.42), pesticides (OR, 2.83; 95% CI = 1.56-5.11), wood dust (OR, 2.86; 95% CI = 1.54-5.33), and organic solvents (multiple-case WM OR, 4.21; 95% CI = 1.69-10.51) compared with unaffected family members.
  • These data provide clues to both genetic and environmental factors that may influence development of WM.
  • Well-designed case-control studies are needed to confirm these findings.

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3052-6 [18703425.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):146-52 [12720125.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Ann Intern Med. 1980 Dec;93(6):830-2 [6778280.001]
  • [Cites] Acta Med Scand. 1982 May;211(3):237-9 [6805257.001]
  • [Cites] Acta Med Scand. 1986;220(4):369-73 [3099545.001]
  • [Cites] Clin Exp Immunol. 1987 May;68(2):397-401 [3115646.001]
  • [Cites] BMJ. 1989 Feb 25;298(6672):498-9 [2495082.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1554-9 [2505923.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5465s-5467s [1327508.001]
  • [Cites] Leukemia. 1993 Sep;7(9):1363-9 [8371587.001]
  • [Cites] J Occup Med. 1994 Feb;36(2):133-6 [8176510.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3647-53 [8204889.001]
  • [Cites] Scand J Immunol. 1994 Aug;40(2):195-200 [8047841.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1913-9 [7703494.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1078-81 [9506352.001]
  • [Cites] Nature. 1962 Oct 13;196:176-8 [13933388.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2342-3 [16224483.001]
  • [Cites] Pathology. 2005 Dec;37(6):409-19 [16373224.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):488-94 [16357024.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1697-700 [17145609.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5096-103 [17303694.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5063-9 [17785558.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):663-71 [18021080.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1183-8 [17990319.001]
  • [Cites] Haematologica. 2008 Mar;93(3):447-50 [18287133.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):657-66 [18311836.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3388-94 [18239085.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Arch Intern Med. 2008 Sep 22;168(17):1903-9 [18809818.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • (PMID = 20308603.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881498
  •  go-up   go-down


56. Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC: Oral graft-versus-host disease. Oral Dis; 2008 Jul;14(5):396-412
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Graft vs Host Disease / complications. Hematopoietic Stem Cell Transplantation / adverse effects. Mouth Diseases / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Rheumatol. 2005 Oct;19(5):839-58 [16150406.001]
  • [Cites] Ann Hematol. 2005 Oct;84(10):681-5 [16001244.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2903-11 [15972448.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1):31-47 [16399567.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 2):22-30 [16399598.001]
  • [Cites] Semin Hematol. 2006 Jan;43(1):3-10 [16412784.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Feb;101(2):175-83 [16448918.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1717-23 [16278306.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Mar;12(3):252-66 [16503494.001]
  • [Cites] Exp Hematol. 2006 Mar;34(3):389-96 [16543073.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):375-96 [16545722.001]
  • [Cites] Annu Rev Immunol. 2006;24:571-606 [16551260.001]
  • [Cites] Leukemia. 2006 Jan;20(1):172-3 [16239908.001]
  • [Cites] Bone Marrow Transplant. 2006 May;37(10):955-9 [16565740.001]
  • [Cites] Arthritis Rheum. 2006 Jun;54(6):1982-6 [16732546.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jul;12(7):792-4 [16785070.001]
  • [Cites] Blood. 2006 Jul 15;108(2):756-62 [16551963.001]
  • [Cites] Immunol Rev. 2006 Aug;212:28-50 [16903904.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2867-73 [16788100.001]
  • [Cites] Curr Opin Hematol. 2006 Nov;13(6):426-35 [17053454.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3216-22 [16835378.001]
  • [Cites] Ann Intern Med. 1977 Dec;87(6):703-6 [22306.001]
  • [Cites] Ann Intern Med. 1977 Dec;87(6):707-9 [22307.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] Hum Pathol. 1981 Nov;12(11):1022-30 [7033104.001]
  • [Cites] Hum Pathol. 1983 Jan;14(1):29-35 [6339354.001]
  • [Cites] Transplantation. 1983 May;35(5):441-6 [6342224.001]
  • [Cites] Age Ageing. 1984 May;13(3):159-65 [6731173.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):292-7 [3883055.001]
  • [Cites] J Invest Dermatol. 1985 Jul;85(1 Suppl):124s-128s [3891878.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1985 Nov;60(5):498-504 [3903599.001]
  • [Cites] Transplantation. 1987 May;43(5):677-9 [3033856.001]
  • [Cites] Transplantation. 1988 Aug;46(2):238-40 [3043780.001]
  • [Cites] Clin Exp Immunol. 1988 May;72(2):267-73 [2970353.001]
  • [Cites] Bone Marrow Transplant. 1988 Jan;3(1):43-51 [3048469.001]
  • [Cites] Arch Pathol Lab Med. 1989 Aug;113(8):932-4 [2757495.001]
  • [Cites] NCI Monogr. 1990;(9):135-43 [2188151.001]
  • [Cites] Blood. 1990 Jul 1;76(1):228-34 [2194590.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6301-5 [2117278.001]
  • [Cites] J Am Dent Assoc. 1991 Mar;122(3):63-9 [2019691.001]
  • [Cites] Transpl Int. 1991 Jun;4(2):96-8 [1716901.001]
  • [Cites] Blood. 1991 Oct 15;78(8):2120-30 [1912589.001]
  • [Cites] J Med. 1992;23(3-4):161-73 [1479298.001]
  • [Cites] Bone Marrow Transplant. 1994 Jan;13(1):81-6 [8019458.001]
  • [Cites] Arch Dermatol. 1995 Aug;131(8):964-5 [7632078.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3604-9 [7579470.001]
  • [Cites] Bone Marrow Transplant. 1996 Feb;17(2):219-24 [8640170.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):158-62 [8762872.001]
  • [Cites] J Invest Dermatol. 1996 Aug;107(2):235-42 [8757769.001]
  • [Cites] Curr Opin Immunol. 1996 Feb;8(1):75-81 [8729449.001]
  • [Cites] Bone Marrow Transplant. 1996 Jun;17(6):1105-11 [8807122.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Jan;81(1):38-43 [8850481.001]
  • [Cites] Int J Oral Maxillofac Surg. 1996 Aug;25(4):298-307 [8910118.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Nov;82(5):556-63 [8936521.001]
  • [Cites] Crit Rev Oral Biol Med. 1997;8(2):201-16 [9167093.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1177-85 [9780337.001]
  • [Cites] Aging (Milano). 1998 Oct;10(5):421-8 [9932146.001]
  • [Cites] Blood. 1999 May 15;93(10):3267-75 [10233878.001]
  • [Cites] Bone Marrow Transplant. 1999 May;23(10):1007-11 [10373066.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2590-8 [15602019.001]
  • [Cites] Dent Clin North Am. 2005 Apr;49(2):309-26 [15755407.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2973-8 [15613541.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):265-74 [15795914.001]
  • [Cites] Blood. 2005 May 15;105(10):3802-11 [15687239.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jun;99(6):696-703 [15897856.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4191-9 [15701715.001]
  • [Cites] J Oral Pathol Med. 2005 Jul;34(6):368-73 [15946186.001]
  • [Cites] Clin Lab Haematol. 2005 Aug;27(4):247-9 [16048492.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):115-21 [15908969.001]
  • [Cites] J Oral Pathol Med. 2005 Sep;34(8):486-93 [16091116.001]
  • [Cites] Oral Microbiol Immunol. 2005 Oct;20(5):282-8 [16101963.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Sep;11(9):721-31 [16125643.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):31-3 [17222750.001]
  • [Cites] Exp Hematol. 2007 Feb;35(2):184-92 [17258067.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(7):431-4 [17310130.001]
  • [Cites] Am J Hematol. 2007 May;82(5):349-56 [17109390.001]
  • [Cites] Pediatr Transplant. 2007 May;11(3):306-11 [17430488.001]
  • [Cites] Nat Rev Immunol. 2007 May;7(5):340-52 [17438575.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2751-8 [17138825.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):327-36 [17433868.001]
  • [Cites] Blood. 2007 Jul 1;110(1):237-41 [17363728.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):273-7 [17549053.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):2013-22 [17641069.001]
  • [Cites] Nat Rev Immunol. 2007 Aug;7(8):585-98 [17653126.001]
  • [Cites] Ann Pharmacother. 2007 Sep;41(9):1436-44 [17684033.001]
  • [Cites] Transl Res. 2007 Oct;150(4):197-214 [17900507.001]
  • [Cites] N Engl J Med. 2007 Oct 11;357(15):1472-5 [17928594.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6107-14 [17947475.001]
  • [Cites] Oral Dis. 2007 Nov;13(6):519-29 [17944667.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3804-13 [17693581.001]
  • [Cites] Dent Clin North Am. 2008 Jan;52(1):61-77, viii [18154865.001]
  • [Cites] Dent Clin North Am. 2008 Jan;52(1):79-109, viii-ix [18154866.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):110-5 [18158967.001]
  • [Cites] Acta Derm Venereol. 2002;82(6):453-5 [12575854.001]
  • [Cites] Annu Rev Immunol. 2003;21:305-34 [12471050.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Mar;95(3):308-11 [12627101.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Aug;9(8):505-11 [12931119.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1095-107 [14523046.001]
  • [Cites] Blood Rev. 2003 Dec;17(4):187-94 [14556773.001]
  • [Cites] Exp Hematol. 2003 Dec;31(12):1187-97 [14662324.001]
  • [Cites] J Dent Res. 2004 Feb;83(2):98-103 [14742644.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Mar;10(3):178-85 [14993883.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2410-6 [14604970.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] Blood. 2004 May 15;103(10):3655-61 [14751924.001]
  • [Cites] Blood. 2004 May 15;103(10):3986-8 [14764530.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2004 Aug;20(4):184-90 [15238096.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):811-4 [15288836.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Harvey Lect. 1966-1967;62:21-78 [4875305.001]
  • [Cites] J Clin Pathol. 1968 Sep;21(5):656-60 [5697370.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1974 Jan;37(1):64-74 [4586901.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1974 Feb;37(2):217-29 [4589360.001]
  • [Cites] Ann Intern Med. 1999 Nov 16;131(10):738-44 [10577296.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(3A):327-34 [10905770.001]
  • [Cites] Ann Intern Med. 2000 Aug 15;133(4):275-9 [10929168.001]
  • [Cites] Arch Oral Biol. 2001 Aug;46(8):689-95 [11389860.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1581-9 [11413166.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1695-700 [11535499.001]
  • [Cites] Bone Marrow Transplant. 2001 Jun;27(12):1275-81 [11548845.001]
  • [Cites] Arch Dermatol. 2001 Sep;137(9):1202-6 [11559218.001]
  • [Cites] Bone Marrow Transplant. 2001 Dec;28(12):1145-50 [11803357.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3050-6 [11929799.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] Blood. 2002 Jul 15;100(2):415-9 [12091330.001]
  • [Cites] Arthritis Rheum. 2002 Oct 15;47(5):520-4 [12382301.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3128-34 [12384409.001]
  • [Cites] Curr Opin Hematol. 2002 Nov;9(6):490-6 [12394170.001]
  • (PMID = 18593456.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 DE999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Denmark
  • [Number-of-references] 132
  • [Other-IDs] NLM/ NIHMS54917; NLM/ PMC2565862
  •  go-up   go-down


57. Askling J, Brandt L, Lapidus A, Karlén P, Björkholm M, Löfberg R, Ekbom A: Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut; 2005 May;54(5):617-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Hematologic Neoplasms / etiology. Inflammatory Bowel Diseases / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Colitis, Ulcerative / complications. Colitis, Ulcerative / epidemiology. Crohn Disease / complications. Crohn Disease / epidemiology. Epidemiologic Methods. Female. Hospitalization. Humans. Infant. Infant, Newborn. Leukemia, Myeloid / epidemiology. Leukemia, Myeloid / etiology. Lymphoma / epidemiology. Lymphoma / etiology. Male. Middle Aged. Sweden / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1982 Jun;23(6):490-7 [7076024.001]
  • [Cites] Gut. 1980 Dec;21(12):1024-9 [7461462.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2914-21 [4052961.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1569-74 [3742475.001]
  • [Cites] Dig Dis Sci. 1986 Oct;31(10):1025-31 [3463495.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):1021-31 [2394325.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):350-8 [1985033.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):2015-9 [2004319.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Lancet. 1994 May 21;343(8908):1249-52 [7910274.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1675-9 [7958678.001]
  • [Cites] Int J Cancer. 1995 Jan 27;60(3):330-3 [7829239.001]
  • [Cites] Leuk Lymphoma. 1995 Apr;17(3-4):255-62 [8580794.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1339-45 [8613037.001]
  • [Cites] Gut. 1997 Oct;41(4):480-6 [9391246.001]
  • [Cites] Gut. 1998 Feb;42(2):175-9 [9536940.001]
  • [Cites] BMJ. 1998 Jul 18;317(7152):180-1 [9665898.001]
  • [Cites] Dig Dis Sci. 1998 Aug;43(8):1791-3 [9724170.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1047-52 [10201481.001]
  • [Cites] Inflamm Bowel Dis. 1999 May;5(2):98-103 [10338378.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):647-53 [10982757.001]
  • [Cites] J Clin Gastroenterol. 1984 Feb;6(1):33-5 [6583276.001]
  • [Cites] Am J Gastroenterol. 1999 Nov;94(11):3248-53 [10566724.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):145-50 [10710198.001]
  • [Cites] Gut. 2000 Oct;47(4):514-9 [10986211.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2308-12 [11007233.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Inflamm Bowel Dis. 2001 May;7(2):106-12 [11383582.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1101-8 [11472312.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1080-7 [11677199.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1239-42 [11677218.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Dec;15(12):1843-9 [11736713.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):963-70 [12687538.001]
  • [Cites] Gut. 2004 Jun;53(6):780-2 [15138201.001]
  • [Cites] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • [Cites] Vital Health Stat 2. 1980;(84):1-59 [7445446.001]
  • [Cites] J Clin Gastroenterol. 1980 Sep;2(3):225-7 [6935291.001]
  • [CommentIn] Gut. 2005 May;54(5):574-5 [15831895.001]
  • (PMID = 15831904.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774486
  •  go-up   go-down


58. Grossberg AJ, Scarlett JM, Marks DL: Hypothalamic mechanisms in cachexia. Physiol Behav; 2010 Jul 14;100(5):478-89
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This combination is found in a number of disorders including cancer, cystic fibrosis, AIDS, rheumatoid arthritis, renal failure, and Alzheimer's disease.
  • This has led to intense investigation of cachexia and the proposal of numerous hypotheses regarding its etiology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [Cites] Nature. 1997 Jan 9;385(6612):165-8 [8990120.001]
  • [Cites] Leukemia. 1997 Feb;11(2):311-2 [9009099.001]
  • [Cites] Annu Rev Immunol. 1997;15:797-819 [9143707.001]
  • [Cites] Neuropharmacology. 1997 Feb;36(2):217-24 [9144659.001]
  • [Cites] J Am Coll Cardiol. 1997 Aug;30(2):527-32 [9247528.001]
  • [Cites] Science. 1997 Oct 3;278(5335):135-8 [9311920.001]
  • [Cites] Endocrinology. 1997 Oct;138(10):4489-92 [9322969.001]
  • [Cites] Brain Res Bull. 1997;44(3):311-7 [9323447.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1763-73 [9392617.001]
  • [Cites] J Neurosci. 1998 Mar 15;18(6):2247-53 [9482809.001]
  • [Cites] Cytokine. 1998 Feb;10(2):110-4 [9512900.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1275-83 [9543156.001]
  • [Cites] Brain Res Bull. 1998 Mar 15;45(5):507-15 [9570721.001]
  • [Cites] Science. 1998 May 29;280(5368):1378-83 [9603721.001]
  • [Cites] Brain Res. 1998 Jun 8;795(1-2):77-86 [9622598.001]
  • [Cites] Ann N Y Acad Sci. 1998 May 1;840:128-38 [9629245.001]
  • [Cites] Ann N Y Acad Sci. 1998 May 1;840:162-73 [9629248.001]
  • [Cites] Endocrinology. 2010 Feb;151(2):606-16 [20016025.001]
  • [Cites] Neuron. 2010 Jan 14;65(1):94-106 [20152116.001]
  • [Cites] Endocrinology. 2004 Apr;145(4):2035-45 [14715713.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):569-74 [15058305.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2004 Jul;7(4):419-26 [15192445.001]
  • [Cites] Nat Med. 2004 Jul;10(7):734-8 [15220914.001]
  • [Cites] Cell. 2004 Oct 15;119(2):285-98 [15479644.001]
  • [Cites] Diabetologia. 1973 Aug;9(4):294-8 [4767369.001]
  • [Cites] Neurosci Lett. 1994 Sep 26;179(1-2):53-6 [7845624.001]
  • [Cites] Mol Endocrinol. 1994 Oct;8(10):1298-308 [7854347.001]
  • [Cites] Eur J Pharmacol. 1994 Nov 14;265(1-2):99-102 [7883035.001]
  • [Cites] Psychoneuroendocrinology. 1995;20(2):111-6 [7899532.001]
  • [Cites] Am J Physiol. 1995 May;268(5 Pt 2):R1327-31 [7771597.001]
  • [Cites] Protein Sci. 1995 Jan;4(1):3-12 [7773174.001]
  • [Cites] Neuroscience. 1995 Apr;65(3):815-26 [7609880.001]
  • [Cites] Int J Dev Neurosci. 1995 Jun-Jul;13(3-4):167-78 [7572273.001]
  • [Cites] Brain Res. 1995 Oct 16;695(2):279-82 [8556346.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1263-71 [8548812.001]
  • [Cites] Brain Behav Immun. 1995 Sep;9(3):242-6 [8590821.001]
  • [Cites] J Comp Neurol. 1995 Oct 30;361(4):681-98 [8576422.001]
  • [Cites] J Clin Invest. 1996 Apr 15;97(8):1852-9 [8621768.001]
  • [Cites] Nat Med. 1996 May;2(5):589-93 [8616722.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5495-504 [8621407.001]
  • [Cites] Infect Dis Clin North Am. 1996 Mar;10(1):1-20 [8698984.001]
  • [Cites] Brain Res. 1996 Mar 4;711(1-2):163-74 [8680860.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1560-2 [8664130.001]
  • [Cites] Am J Physiol. 1996 Jun;270(6 Pt 2):R1394-402 [8764309.001]
  • [Cites] Neuroreport. 1996 Feb 29;7(3):841-4 [8733758.001]
  • [Cites] Endocrinology. 1996 Jul;137(7):2947-53 [8770918.001]
  • [Cites] J Comp Neurol. 1996 Jul 15;371(1):85-103 [8835720.001]
  • [Cites] Peptides. 1996;17(5):797-801 [8844769.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11008-13 [8855299.001]
  • [Cites] J Neuroimmunol. 1996 Oct;70(1):45-53 [8862134.001]
  • [Cites] Physiol Behav. 1996 Sep;60(3):867-75 [9110949.001]
  • [Cites] J Neuroendocrinol. 1996 Oct;8(10):733-5 [8910801.001]
  • [Cites] Neuron. 1999 Feb;22(2):221-32 [10069329.001]
  • [Cites] Oncologist. 2007 May;12(5):594-600 [17522248.001]
  • [Cites] Endocrinology. 2007 Sep;148(9):4217-25 [17525125.001]
  • [Cites] Nature. 2007 Sep 13;449(7159):228-32 [17728716.001]
  • [Cites] J Neurosci. 2007 Sep 26;27(39):10476-86 [17898219.001]
  • [Cites] Brain Behav Immun. 2007 Nov;21(8):1109-21 [17604949.001]
  • [Cites] Endocrinology. 2007 Nov;148(11):5230-7 [17673516.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3475-88 [17885689.001]
  • [Cites] Endocrinology. 2008 Feb;149(2):827-35 [18039782.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1513-23 [12639936.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Nat Neurosci. 2003 Nov;6(11):1137-8 [14566340.001]
  • [Cites] Neurosci Lett. 2003 Dec 19;353(2):119-22 [14664915.001]
  • [Cites] Am Sci. 1978 Jan-Feb;66(1):38-43 [623399.001]
  • [Cites] Am J Clin Nutr. 1979 Mar;32(3):593-6 [283688.001]
  • [Cites] Physiol Behav. 1981 Aug;27(2):271-7 [7029576.001]
  • [Cites] Brain Res. 1982 Nov;257(3):275-325 [6756545.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):553-8 [6402699.001]
  • [Cites] N Engl J Med. 1984 Mar 1;310(9):596 [6607415.001]
  • [Cites] Lymphokine Res. 1986 Spring;5(2):77-85 [3010001.001]
  • [Cites] Brain Res Bull. 1988 Jan;20(1):75-82 [3124931.001]
  • [Cites] EMBO J. 1987 Dec 20;6(13):3995-4002 [3127201.001]
  • [Cites] Endocrinology. 1988 May;122(5):1773-9 [2834174.001]
  • [Cites] Neurosci Biobehav Rev. 1988 Summer;12(2):123-37 [3050629.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5948-52 [2569739.001]
  • [Cites] Brain Behav Immun. 1988 Dec;2(4):352-8 [3076487.001]
  • [Cites] Endocrinology. 1990 Apr;126(4):2145-52 [2180683.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Dec;25(12):1817-21 [2698804.001]
  • [Cites] N Engl J Med. 1990 Jul 26;323(4):236-41 [2195340.001]
  • [Cites] Physiol Rev. 1991 Jan;71(1):93-127 [1986393.001]
  • [Cites] Brain Res Mol Brain Res. 1991 Jan;9(1-2):143-8 [1850069.001]
  • [Cites] J Infect Dis. 1991 Jun;163(6):1177-84 [2037782.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1991 Mar;21(2):225-37 [2053246.001]
  • [Cites] Neurosci Biobehav Rev. 1991 Summer;15(2):185-215 [1852312.001]
  • [Cites] Eur J Pharmacol. 1991 Mar 26;195(2):281-4 [1908387.001]
  • [Cites] Cytokine. 1990 Sep;2(5):313-29 [2103331.001]
  • [Cites] Cancer Res. 1991 Dec 15;51(24):6656-9 [1742740.001]
  • [Cites] Lancet. 1998 May 2;351(9112):1336 [9643807.001]
  • [Cites] Am J Physiol. 1998 Aug;275(2 Pt 2):R384-9 [9688672.001]
  • [Cites] Biosci Biotechnol Biochem. 1998 Jul;62(7):1318-25 [9720213.001]
  • [Cites] J Comp Neurol. 1998 Oct 19;400(2):175-96 [9766398.001]
  • [Cites] Endocrinology. 1998 Nov;139(11):4483-8 [9794456.001]
  • [Cites] J Biochem. 1998 Nov;124(5):999-1003 [9792925.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15043-8 [9844012.001]
  • [Cites] Int J Mol Med. 1998 Feb;1(2):387-97 [9852241.001]
  • [Cites] Ann N Y Acad Sci. 1998 Sep 29;856:148-59 [9917875.001]
  • [Cites] Cell Metab. 2008 Mar;7(3):236-48 [18316029.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jun;294(6):C1436-42 [18385284.001]
  • [Cites] Anim Health Res Rev. 2008 Jun;9(1):87-99 [18423072.001]
  • [Cites] Clin Exp Rheumatol. 2008 May-Jun;26(3):436-41 [18578965.001]
  • [Cites] J Neuroimmunol. 2008 Aug 13;199(1-2):104-14 [18602702.001]
  • [Cites] Neuroimmunomodulation. 2008;15(2):125-30 [18679051.001]
  • [Cites] Endocrinology. 2008 Oct;149(10):4837-45 [18583425.001]
  • [Cites] J Anim Sci. 2008 Oct;86(10):2557-67 [18502874.001]
  • [Cites] Clin Nutr. 2008 Dec;27(6):793-9 [18718696.001]
  • [Cites] Curr Mol Med. 2008 Dec;8(8):816-28 [19075678.001]
  • [Cites] Metab Brain Dis. 2009 Mar;24(1):55-68 [19067144.001]
  • [Cites] Endocrinology. 2009 Mar;150(3):1182-91 [19008309.001]
  • [Cites] Curr Opin Immunol. 2009 Feb;21(1):63-7 [19231148.001]
  • [Cites] J Rheumatol. 2009 May;36(5):887-92 [19273455.001]
  • [Cites] Cell Metab. 2009 Jun;9(6):537-47 [19490908.001]
  • [Cites] Trends Endocrinol Metab. 2009 Jul;20(5):203-15 [19541496.001]
  • [Cites] J Neurosci. 2009 Oct 14;29(41):12970-81 [19828811.001]
  • [Cites] Endocrinology. 2009 Dec;150(12):5488-97 [19819961.001]
  • [Cites] Endocrinology. 2009 Dec;150(12):5509-19 [19837874.001]
  • [Cites] Auton Neurosci. 2000 Dec 20;85(1-3):127-32 [11189019.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1432-8 [11245447.001]
  • [Cites] Brain Behav Immun. 2001 Mar;15(1):7-24 [11259077.001]
  • [Cites] J Neurosci. 2001 Apr 15;21(8):2669-77 [11306620.001]
  • [Cites] FASEB J. 2001 May;15(7):1169-80 [11344085.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Jun 20;90(2):93-100 [11406287.001]
  • [Cites] Neuroreport. 2001 Jul 20;12(10):2155-8 [11447325.001]
  • [Cites] Endocrinology. 2001 Aug;142(8):3292-301 [11459770.001]
  • [Cites] Brain Res. 2001 Aug 10;910(1-2):163-73 [11489266.001]
  • [Cites] Exp Gerontol. 2002 Jan-Mar;37(2-3):411-20 [11772528.001]
  • [Cites] Nat Med. 2002 Jan;8(1):75-9 [11786910.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2001 Dec;15(4):435-51 [11800516.001]
  • [Cites] Pharmacol Res. 2002 Feb;45(2):119-24 [11846623.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Feb;38(3):340-50 [11890981.001]
  • [Cites] J Neuroimmunol. 2002 Apr;125(1-2):5-14 [11960635.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jun;56(6):723-33 [12072041.001]
  • [Cites] J Neurosci. 2002 Jun 15;22(12):5091-9 [12077204.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5027-35 [12077332.001]
  • [Cites] Peptides. 2002 May;23(5):975-84 [12084530.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2002 Oct;283(4):R862-8 [12228055.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):87-90 [12563267.001]
  • [Cites] Nature. 2003 Feb 20;421(6925):856-9 [12594516.001]
  • [Cites] Mol Med Today. 1999 Feb;5(2):79-85 [10200949.001]
  • [Cites] Eur Heart J. 1999 May;20(9):683-93 [10208789.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7220-5 [10377395.001]
  • [Cites] J Neurochem. 1999 Jul;73(1):309-21 [10386984.001]
  • [Cites] Adv Exp Med Biol. 1999;461:199-233 [10442175.001]
  • [Cites] Neuron. 1999 Aug;23(4):775-86 [10482243.001]
  • [Cites] Neuroscience. 1999;93(4):1449-64 [10501470.001]
  • [Cites] Br Heart J. 1962 May;24:257-64 [14454369.001]
  • [Cites] J Exp Med. 1963 Oct 1;118:649-58 [14067912.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2005 May;8(3):265-9 [15809528.001]
  • [Cites] Nat Neurosci. 2005 May;8(5):571-8 [15856065.001]
  • [Cites] Eur J Neurosci. 2005 Apr;21(8):2233-42 [15869520.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2766-73 [15774557.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1659-65 [15931394.001]
  • [Cites] Cell Metab. 2005 Jan;1(1):63-72 [16054045.001]
  • [Cites] J Am Coll Cardiol. 2005 Sep 20;46(6):1019-26 [16168285.001]
  • [Cites] Diabetes. 2005 Dec;54(12):3503-9 [16306368.001]
  • [Cites] Diabetes. 2006 Apr;55(4):971-7 [16567518.001]
  • [Cites] Diabetes. 2006 May;55(5):1205-13 [16644674.001]
  • [Cites] Physiol Genomics. 2006 May 16;25(3):485-92 [16554545.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10707-12 [16818888.001]
  • [Cites] Cell Metab. 2006 Aug;4(2):123-32 [16890540.001]
  • [Cites] Obesity (Silver Spring). 2006 Aug;14 Suppl 5:234S-237S [17021373.001]
  • [Cites] Vitam Horm. 2006;74:229-54 [17027517.001]
  • [Cites] Regul Pept. 2007 Apr 5;140(1-2):94-100 [17187875.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):841-9 [17404609.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):374-83 [17360153.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):3004-12 [17347304.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Dec;259(3):988-96 [1762091.001]
  • [Cites] Life Sci. 1992;51(18):1419-26 [1406057.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9117-20 [1409612.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):152-4 [8418227.001]
  • [Cites] Br J Pharmacol. 1993 Jun;109(2):289-90 [8358531.001]
  • [Cites] J Neuroimmunol. 1993 Sep;47(2):169-76 [8370768.001]
  • [Cites] Brain Res Bull. 1993;32(6):581-7 [8221156.001]
  • [Cites] J Neurosci. 1994 Feb;14(2):897-913 [8301368.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):R125-35 [8304533.001]
  • [Cites] Lymphokine Cytokine Res. 1994 Apr;13(2):107-12 [8061111.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] J Infect Dis. 1995 Jan;171(1):232-6 [7798671.001]
  • [Cites] Ann N Y Acad Sci. 1994 Oct 31;739:311-4 [7832483.001]
  • [Cites] Glia. 1996 Oct;18(2):141-51 [8913777.001]
  • [Cites] Am J Physiol. 1996 Nov;271(5 Pt 2):R1142-8 [8945946.001]
  • [Cites] J Neurochem. 2000 Feb;74(2):457-71 [10646496.001]
  • [Cites] Brain Res Bull. 2000 Jan 1;51(1):3-9 [10654575.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2143-51 [10811680.001]
  • [Cites] J Neuroendocrinol. 2000 Jun;12(6):501-5 [10844578.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):313-45 [10857556.001]
  • [Cites] Cytokine. 2000 May;12(5):423-31 [10857755.001]
  • [Cites] Horm Behav. 2000 Jun;37(4):299-305 [10860674.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Jul;279(1):R47-52 [10896863.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Jul;279(1):R93-8 [10896869.001]
  • [Cites] Science. 2000 Sep 29;289(5488):2363-6 [11009425.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32783-92 [10869354.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4032-40 [11089533.001]
  • [Cites] Eur J Neurosci. 2000 Dec;12(12):4434-46 [11122354.001]
  • (PMID = 20346963.001).
  • [ISSN] 1873-507X
  • [Journal-full-title] Physiology & behavior
  • [ISO-abbreviation] Physiol. Behav.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK070333-07; United States / NIDDK NIH HHS / DK / R01 DK070333; United States / NIDDK NIH HHS / DK / R01 DK070333-07
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Melanocortins; 0 / Neuropeptide Y
  • [Number-of-references] 203
  • [Other-IDs] NLM/ NIHMS218647; NLM/ PMC2927357
  •  go-up   go-down


59. Neusser MA, Lindenmeyer MT, Moll AG, Segerer S, Edenhofer I, Sen K, Stiehl DP, Kretzler M, Gröne HJ, Schlöndorff D, Cohen CD: Human nephrosclerosis triggers a hypoxia-related glomerulopathy. Am J Pathol; 2010 Feb;176(2):594-607
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human nephrosclerosis triggers a hypoxia-related glomerulopathy.
  • In the kidney, hypoxia contributes to tubulointerstitial fibrosis, but little is known about its implications for glomerular damage and glomerulosclerosis.
  • Chronic hypoxia was hypothesized to be involved in nephrosclerosis (NSC) or "hypertensive nephropathy."
  • In the present study genome-wide expression data from microdissected glomeruli were studied to examine the role of hypoxia in glomerulosclerosis of human NSC.
  • Functional annotation analysis revealed prominent regulation of hypoxia-associated biological processes in NSC, including angiogenesis, fibrosis, and inflammation.
  • Glomerular expression levels of a majority of genes regulated by the hypoxia-inducible factors (HIFs) were significantly altered in NSC.
  • Among these HIF targets, chemokine C-X-C motif receptor 4 (CXCR4) was prominently induced.
  • Glomerular CXCR4 mRNA induction was confirmed by quantitative RT-PCR in an independent cohort with NSC but not in those with other glomerulopathies.
  • By immunohistological analysis, CXCR4 showed enhanced positivity in podocytes in NSC biopsy specimens.
  • This CXCR4 positivity was associated with nuclear localization of HIF1alpha only in podocytes of NSC, indicating transcriptional activity of HIF.
  • As the CXCR4 ligand CXCL12/SDF-1 is constitutively expressed in podocytes, autocrine signaling may contribute to NSC.
  • In addition, a blocking CXCR4 antibody caused significant inhibition of wound closure by podocytes in an in vitro scratch assay.
  • These data support a role for CXCR4/CXCL12 in human NSC and indicate that hypoxia not only is involved in tubulointerstitial fibrosis but also contributes to glomerular damage in NSC.

  • Genetic Alliance. consumer health - Nephrosclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2008 Nov;19(11):2047-51 [18923054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Am Soc Nephrol. 2009 Feb;20(2):333-43 [19092119.001]
  • [Cites] J Am Soc Nephrol. 2009 Feb;20(2):322-32 [19092120.001]
  • [Cites] PLoS One. 2009;4(3):e4702 [19277110.001]
  • [Cites] Dev Dyn. 2009 May;238(5):1083-91 [19384956.001]
  • [Cites] J Am Soc Nephrol. 2009 Aug;20(8):1714-23 [19443644.001]
  • [Cites] Kidney Int. 2002 Jul;62(1):172-80 [12081576.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1721-32 [12089367.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1992-2003 [12357350.001]
  • [Cites] J Am Soc Nephrol. 2003 Apr;14(4):927-38 [12660327.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2543-56 [12815141.001]
  • [Cites] J Pathol. 2003 Jul;200(4):526-36 [12845620.001]
  • [Cites] Nature. 2003 Sep 18;425(6955):307-11 [13679920.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] J Exp Med. 2003 Nov 3;198(9):1391-402 [14597738.001]
  • [Cites] FEBS Lett. 2004 Jan 2;556(1-3):137-42 [14706840.001]
  • [Cites] Nat Med. 2004 Aug;10(8):858-64 [15235597.001]
  • [Cites] Kidney Int. 1991 Nov;40(5):906-12 [1662315.001]
  • [Cites] Am J Kidney Dis. 1994 May;23(5):655-60 [8172207.001]
  • [Cites] Am J Kidney Dis. 1995 Feb;25(2):207-21 [7847347.001]
  • [Cites] J Pathol. 1995 Nov;177(3):259-67 [8551388.001]
  • [Cites] Kidney Int. 1997 Jan;51(1):244-52 [8995739.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):248-58 [9344605.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Jan;288(1):F236-42 [15583217.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):105-15 [15630139.001]
  • [Cites] Blood. 2005 Jan 15;105(2):659-69 [15374877.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):1071-80 [15731012.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1800-7 [15753377.001]
  • [Cites] Trends Cardiovasc Med. 2005 Feb;15(2):57-63 [15885571.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6178-88 [16024619.001]
  • [Cites] Sci STKE. 2005 Oct 18;2005(306):re12 [16234508.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5682-7 [16581909.001]
  • [Cites] Kidney Int. 2006 Apr;69(8):1302-7 [16531988.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Aug;291(2):F271-81 [16554418.001]
  • [Cites] Nat Clin Pract Nephrol. 2006 Feb;2(2):101-8 [16932401.001]
  • [Cites] J Am Soc Nephrol. 2006 Sep;17(9):2443-56 [16885410.001]
  • [Cites] Transl Res. 2006 Sep;148(3):142-8 [16938652.001]
  • [Cites] Nat Med. 2006 Sep;12(9):1081-7 [16906157.001]
  • [Cites] Mol Cell Neurosci. 2006 Oct;33(2):160-9 [16952464.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1133-8 [17016644.001]
  • [Cites] Diabetes. 2006 Nov;55(11):2993-3003 [17065335.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Mar;292(3):F905-11 [17190907.001]
  • [Cites] Kidney Int. 2007 Apr;71(7):637-45 [17264876.001]
  • [Cites] PLoS One. 2007;2(5):e416 [17476338.001]
  • [Cites] Oncogene. 2007 May 17;26(23):3329-37 [17130833.001]
  • [Cites] J Am Soc Nephrol. 2007 Jun;18(6):1765-76 [17475821.001]
  • [Cites] Hypertens Res. 2007 Jul;30(7):635-42 [17785932.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Oct;293(4):F1397-407 [17609290.001]
  • [Cites] J Nephrol. 2007 Sep-Oct;20(5):518-24 [17918136.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3810-20 [18037992.001]
  • [Cites] Arthritis Rheum. 2007 Dec;56(12):4203-15 [18050252.001]
  • [Cites] Nat Clin Pract Nephrol. 2008 Jan;4(1):24-37 [18094725.001]
  • [Cites] Am J Pathol. 2008 Feb;172(2):299-308 [18202193.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):479-90 [18268039.001]
  • [Cites] Mol Cell Neurosci. 2008 May;38(1):43-52 [18343155.001]
  • [Cites] Pediatr Nephrol. 2000 Dec;15(3-4):290-301 [11149129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2001 May;10(3):315-20 [11342792.001]
  • [Cites] Kidney Int. 2002 Jan;61(1):133-40 [11786093.001]
  • [Cites] J Am Soc Nephrol. 2002 Mar;13(3):630-8 [11856766.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):957-67 [11912255.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):6244-52 [12055238.001]
  • [Cites] Cell Cycle. 2008 May 1;7(9):1128-32 [18418042.001]
  • [Cites] Nature. 2008 Jun 5;453(7196):807-11 [18432192.001]
  • [Cites] Kidney Int. 2008 Jul;74(1):37-46 [18368027.001]
  • [Cites] Histochem Cell Biol. 2008 Aug;130(2):247-62 [18575881.001]
  • [Cites] PLoS One. 2008;3(8):e2937 [18698414.001]
  • [Cites] Kidney Int. 2008 Oct;74(7):867-72 [18633339.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1185-92 [18794854.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1175-84 [18794856.001]
  • (PMID = 20019191.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK079912; United States / NIDDK NIH HHS / DK / R01 DK081420; United States / NIDDK NIH HHS / DK / R01-DK081420-01
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2808068
  •  go-up   go-down


60. Bertrand KA, Birmann BM, Chang ET, Spiegelman D, Aster JC, Zhang SM, Laden F: A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma. Blood; 2010 Nov 4;116(18):3547-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For chronic lymphocytic leukemia/small lymphocytic lymphoma, suggestive associations were noted for elevated anti-EBNA-2 (RR, 1.74; 95% CI, 0.99-3.05), anti-viral capsid antigen (RR, 1.58; 95% CI, 0.79-3.14), and EBNA-1/EBNA-2 ratio ≤ 1.0 (RR, 1.52; 95% CI, 0.91-2.55).
  • Overall, we found no evidence that EBV antibody profile predicts NHL risk in immunocompetent persons, with the possible exception of chronic lymphocytic leukemia/small lymphocytic lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1751-8 [10528026.001]
  • [Cites] Epidemiology. 2010 Mar;21(2):172-80 [20087190.001]
  • [Cites] J Epidemiol Community Health. 2000 Jun;54(6):431-6 [10818118.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • [Cites] Arthritis Rheum. 2001 May;44(5):1122-6 [11352244.001]
  • [Cites] Int J Exp Pathol. 2001 Jun;82(3):149-70 [11488990.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):619-29 [11697490.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4222-5 [6272966.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jan;84(2):570-4 [3025881.001]
  • [Cites] J Med Virol. 1987 Feb;21(2):109-21 [3029317.001]
  • [Cites] Stat Med. 1989 May;8(5):551-61 [2657958.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):129-35 [2664509.001]
  • [Cites] J Infect Dis. 1990 May;161(5):903-9 [2157771.001]
  • [Cites] Int J Cancer. 1991 Sep 30;49(3):387-93 [1655660.001]
  • [Cites] Cancer Causes Control. 1993 May;4(3):187-93 [8391336.001]
  • [Cites] Eur J Cancer. 1993;29A(11):1584-9 [8217366.001]
  • [Cites] Am J Epidemiol. 1994 Dec 1;140(11):1016-9 [7985649.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):761-8 [9125261.001]
  • [Cites] Lancet. 1997 Jul 26;350(9073):240-4 [9242800.001]
  • [Cites] Immunity. 1998 Sep;9(3):395-404 [9768759.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S5-10 [10430211.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1564-70 [17443495.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1806-12 [17557295.001]
  • [Cites] Annu Rev Pathol. 2006;1:375-404 [18039120.001]
  • [Cites] Lancet Oncol. 2008 Nov;9(11):1039-47 [18835745.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Nat Rev Immunol. 2008 Sep;8(9):737-44 [18728636.001]
  • [Cites] Oncol Rep. 2009 Jun;21(6):1567-76 [19424638.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Apr;34(1):27-53 [10781747.001]
  • (PMID = 20647565.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098122; United States / NHLBI NIH HHS / HL / HL26490; United States / NHLBI NIH HHS / HL / HL34595; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / CA34944; United States / NCI NIH HHS / CA / K07 CA115687; United States / NHLBI NIH HHS / HL / R01 HL034595; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / CA098122; United States / NCI NIH HHS / CA / R25 CA098566; United States / NCI NIH HHS / CA / CA097193; United States / NHLBI NIH HHS / HL / R01 HL026490; United States / NCI NIH HHS / CA / R01 CA040360; United States / NIEHS NIH HHS / ES / T32 ES007155; United States / NCI NIH HHS / CA / R01 CA097193; United States / NCI NIH HHS / CA / CA40360; United States / NCI NIH HHS / CA / R01 CA034944
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Epstein-Barr virus early antigen
  • [Other-IDs] NLM/ PMC2981477
  •  go-up   go-down


61. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA: Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer; 2009 Mar 10;100(5):822-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specifically, AML was associated with rheumatoid arthritis (OR 1.28), systemic lupus erythematosus (OR 1.92), polymyalgia rheumatica (OR 1.73), autoimmune haemolytic anaemia (OR 3.74), systemic vasculitis (OR 6.23), ulcerative colitis (OR 1.72) and pernicious anaemia (OR 1.57).
  • Myelodysplastic syndrome was associated with rheumatoid arthritis (OR1.52) and pernicious anaemia (OR 2.38).
  • [MeSH-major] Autoimmune Diseases / complications. Myelodysplastic Syndromes / etiology. Myelodysplastic-Myeloproliferative Diseases / etiology. Myeloproliferative Disorders / etiology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3069-75 [18957521.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):41-5 [11437400.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):320-2 [11703328.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Clin Rheumatol. 2002 Aug;21(4):309-13 [12189460.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):603-8 [12296507.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):147 [14508809.001]
  • [Cites] Ann Pharmacother. 2004 Jan;38(1):172-3 [14742816.001]
  • [Cites] Eur J Haematol. 2004 Aug;73(2):128-33 [15245512.001]
  • [Cites] Eur J Clin Invest. 2004 Oct;34(10):690-700 [15473894.001]
  • [Cites] Am J Med Sci. 1977 May-Jun;273(3):335-40 [266841.001]
  • [Cites] Br J Cancer. 1989 Apr;59(4):639-44 [2713251.001]
  • [Cites] Am J Med. 1990 Feb;88(2):197-9 [2301449.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):745-50 [8431855.001]
  • [Cites] Cancer Causes Control. 1993 Jul;4(4):361-8 [8347786.001]
  • [Cites] Br J Rheumatol. 1996 May;35(5):496-7 [8646448.001]
  • [Cites] Cytokines Mol Ther. 1996 Dec;2(4):239-42 [9384710.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):94-7 [9666800.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1088-95 [15625654.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):634-8 [15609330.001]
  • [Cites] Acta Haematol. 2005;113(2):146-9 [15802895.001]
  • [Cites] Gut. 2005 May;54(5):617-22 [15831904.001]
  • [Cites] Cancer Causes Control. 2005 Jun;16(5):489-500 [15986104.001]
  • [Cites] Cancer Causes Control. 2005 Oct;16(8):939-53 [16132803.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1414-20 [15843454.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1912-8 [16167059.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):3028-33 [16945522.001]
  • [Cites] J Clin Rheumatol. 2007 Apr;13(2):114 [17414547.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Arch Environ Occup Health. 2007 Fall;62(3):131-7 [18400653.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1417-21 [18561319.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):927-35 [11298587.001]
  • [CommentIn] Acta Haematol. 2016;136(2):108-17 [27337745.001]
  • (PMID = 19259097.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653768
  •  go-up   go-down


62. Toffalini F, Hellberg C, Demoulin JB: Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. J Biol Chem; 2010 Apr 16;285(16):12268-78
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line. Cell Proliferation. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cytosol / metabolism. Humans. Leukemia, Myeloid / etiology. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Molecular Sequence Data. Myeloid Cells / metabolism. Myeloid Cells / pathology. Protein Structure, Tertiary. Recombinant Proteins / chemistry. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Sequence Deletion. Signal Transduction. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1992 Jan;11(1):43-8 [1346763.001]
  • [Cites] J Cell Biol. 1991 Feb;112(3):469-78 [1846866.001]
  • [Cites] Cell. 1994 Apr 22;77(2):307-16 [8168137.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4710-6 [8756628.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14845-50 [8962143.001]
  • [Cites] EMBO J. 1997 Jan 2;16(1):69-82 [9009269.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):349-57 [9018121.001]
  • [Cites] J Virol. 1997 Oct;71(10):7318-27 [9311809.001]
  • [Cites] Oncogene. 1998 Jan 29;16(4):505-15 [9484840.001]
  • [Cites] EMBO J. 1998 Dec 1;17(23):6912-23 [9843497.001]
  • [Cites] Cell Mol Life Sci. 2004 Dec;61(23):2912-23 [15583853.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):41893-9 [16239216.001]
  • [Cites] J Biol Chem. 2006 Mar 17;281(11):7002-11 [16414957.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8078-83 [16690743.001]
  • [Cites] Growth Factors. 2006 Sep;24(3):184-96 [17079202.001]
  • [Cites] Haematologica. 2007 Feb;92(2):163-9 [17296564.001]
  • [Cites] Nat Protoc. 2007;2(4):953-71 [17446895.001]
  • [Cites] Blood. 2007 May 1;109(9):3906-14 [17218386.001]
  • [Cites] Cell. 2007 Jul 27;130(2):323-34 [17662946.001]
  • [Cites] Mol Biol Cell. 2008 Feb;19(2):646-54 [18045991.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7681-6 [18505839.001]
  • [Cites] Leukemia. 2008 Nov;22(11):1999-2010 [18843283.001]
  • [Cites] Exp Hematol. 2009 Jan;37(1):111-121 [19100521.001]
  • [Cites] Arthritis Rheum. 2009 Apr;60(4):1137-44 [19333949.001]
  • [Cites] J Biol Chem. 2009 Apr 17;284(16):10334-42 [19244250.001]
  • [Cites] Mol Biol Cell. 2009 Jun;20(12):2856-63 [19369415.001]
  • [Cites] Haematologica. 2009 Aug;94(8):1085-93 [19644140.001]
  • [Cites] Biochim Biophys Acta. 2010 Mar;1798(3):605-15 [20036637.001]
  • [Cites] Oncogene. 1999 Nov 25;18(50):7055-62 [10597306.001]
  • [Cites] J Clin Invest. 2000 Feb;105(4):423-32 [10683371.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1938-42 [10988075.001]
  • [Cites] FEBS Lett. 2000 Oct 6;482(3):200-4 [11024460.001]
  • [Cites] Mol Biol Cell. 2000 Oct;11(10):3589-99 [11029057.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3390-7 [11719379.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4704-12 [11741943.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38627-34 [12181311.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47149-59 [12351659.001]
  • [Cites] Mol Cell Biol. 2003 May;23(9):3067-78 [12697809.001]
  • [Cites] Biochem J. 2003 Dec 1;376(Pt 2):505-10 [12967325.001]
  • [Cites] Mol Cell. 2003 Nov;12(5):1239-50 [14636581.001]
  • [Cites] Mol Cell. 2004 Jan 30;13(2):169-78 [14759363.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):2190-201 [14966296.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):19732-8 [14996833.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35392-402 [15213220.001]
  • [Cites] Growth Factors. 1992;6(1):1-14 [1317195.001]
  • (PMID = 20164181.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Recombinant Proteins; 0 / TEL-PDGFRbeta fusion protein, human
  • [Other-IDs] NLM/ PMC2852966
  •  go-up   go-down


63. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford); 2010 Feb;49(2):271-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / drug effects. Biopsy. Cell Adhesion Molecules / metabolism. Collagen / metabolism. Drug Administration Schedule. Humans. Lung Diseases, Interstitial / drug therapy. Lung Diseases, Interstitial / etiology. Lung Diseases, Interstitial / physiopathology. Lymphocyte Depletion / methods. Middle Aged. Respiratory Function Tests / methods. Rituximab. Skin / immunology. Skin / metabolism. Skin / pathology. Tomography, X-Ray Computed. Vital Capacity / drug effects

  • Genetic Alliance. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 1991 Oct;18(10):1520-8 [1765976.001]
  • [Cites] Arch Intern Med. 1993 Jun 14;153(11):1337-42 [8507124.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):559-62 [9492775.001]
  • [Cites] Lancet. 1999 Jul 17;354(9174):220 [10421308.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):501-13 [15693003.001]
  • [Cites] J Rheumatol. 2005 May;32(5):832-40 [15868618.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4885-91 [15746077.001]
  • [Cites] Curr Opin Rheumatol. 2005 Nov;17(6):746-51 [16224253.001]
  • [Cites] Transplantation. 2006 Feb 27;81(4):573-82 [16495806.001]
  • [Cites] Leukemia. 2006 Jan;20(1):172-3 [16239908.001]
  • [Cites] Drugs. 2006;66(8):1041-57 [16789791.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2655-66 [16790698.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2667-76 [16790699.001]
  • [Cites] Blood. 2006 Jul 15;108(2):756-62 [16551963.001]
  • [Cites] Rheumatology (Oxford). 2006 Aug;45(8):1005-8 [16490756.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):954-66 [16936269.001]
  • [Cites] Rheumatology (Oxford). 2006 Dec;45(12):1572 [16998235.001]
  • [Cites] Ann Rheum Dis. 2003 Sep;62(9):904-5 [12922969.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12319-24 [14530402.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1721-33 [15188347.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1918-27 [15188368.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):641-50 [15277237.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2603-6 [15251978.001]
  • [Cites] Mol Immunol. 2004 Nov;41(12):1123-33 [15482848.001]
  • [Cites] Arthritis Rheum. 1980 May;23(5):581-90 [7378088.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Dec;2(12):679-85 [17133253.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3962-70 [17133610.001]
  • [Cites] Rheumatol Int. 2007 Feb;27(4):357-61 [17021713.001]
  • [Cites] Rheumatology (Oxford). 2007 Mar;46(3):442-5 [16899504.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):66-73 [17275413.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):349-60 [17448966.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):623-4 [17454609.001]
  • [Cites] Ann Rheum Dis. 2007 Jul;66(7):966-9 [17234649.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1388-96 [17452515.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):3167-8 [17763433.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34 [17717203.001]
  • [Cites] Nephrology (Carlton). 2007 Dec;12(6):553-8 [17995580.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):552-3 [18281368.001]
  • [Cites] Arthritis Rheum. 2009 Feb;60(2):578-83 [19180481.001]
  • [Cites] Ann Rheum Dis. 2010 Jan;69(1):193-7 [19103636.001]
  • [Cites] Arthritis Care Res. 1991 Mar;4(1):27-31 [11188583.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):329-34 [11759059.001]
  • [CommentIn] Rheumatology (Oxford). 2010 Feb;49(2):201-2 [20032221.001]
  • (PMID = 19447770.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cell Adhesion Molecules; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC2806066
  •  go-up   go-down


64. Csako G, Costello R, Shamim EA, O'Hanlon TP, Tran A, Clauw DJ, Williams HJ, Miller FW: Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study. Arthritis Res Ther; 2007;9(5):R95
MedlinePlus Health Information. consumer health - Connective Tissue Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study.
  • Prior studies have suggested abnormalities of serum proteins, including paraproteins, in women with silicone implants but did not control for the presence of connective-tissue disease (CTD).
  • This retrospective case-control study, performed in tertiary-care academic centers, assessed possible alterations of serum proteins, including paraproteins, in such a population.
  • Seventy-four women with silicone implants who subsequently developed CTD, and 74 age-matched and CTD-matched women without silicone implants, were assessed in the primary study; other groups were used for additional comparisons.
  • Routine serum protein determinations and high-sensitivity protein electrophoresis and immunofixation electrophoresis were performed for detection of paraproteins.
  • Women with silicone implants, either with or without CTD, had significantly lower serum total protein and alpha1-globulin, alpha2-globulin, beta-globulin, gamma-globulin, and IgG levels compared with those without silicone implants.
  • There was no significant difference, however, in the frequency of paraproteinemia between women with silicone implants and CTD (9.5%) and age-matched and CTD-matched women without silicone implants (5.4%) (odds ratio, 1.82; 95% confidence interval, 0.51-6.45).
  • Paraprotein isotypes were similar in the two groups, and the clinical characteristics of the 13 women with paraproteinemia were comparable with an independent population of 10 women with silicone breast implants, CTD, and previously diagnosed monoclonal gammopathies.
  • In summary, this first comprehensive study of serum proteins in women with silicone implants and CTD found no substantially increased risk of monoclonal gammopathy.
  • Women with silicone implants, however, had unexpectedly low serum globulin and immunoglobulin levels, with or without the subsequent development of CTD.
  • The causes and clinical implications of these findings require further investigation.

  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):781-90 [10717013.001]
  • [Cites] J Natl Cancer Inst. 1994 Jul 20;86(14):1058-65 [8021954.001]
  • [Cites] Aust N Z J Med. 1999 Aug;29(4):500-4 [10868527.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1975-9 [11069034.001]
  • [Cites] Arch Intern Med. 2001 Mar 26;161(6):864-7 [11268230.001]
  • [Cites] Ann Plast Surg. 2004 Nov;53(5):413-9 [15502454.001]
  • [Cites] Acta Med Scand. 1966 Feb;179(2):235-47 [4160039.001]
  • [Cites] Ann N Y Acad Sci. 1971 Dec 31;190:507-18 [5003017.001]
  • [Cites] Medicine (Baltimore). 1977 Jul;56(4):255-86 [327194.001]
  • [Cites] J Clin Pathol. 1982 Jan;35(1):63-8 [6801095.001]
  • [Cites] Scand J Haematol. 1986 Jan;36(1):103-6 [3081993.001]
  • [Cites] J Rheumatol. 1988 Jun;15(6):894-8 [3262160.001]
  • [Cites] Arthritis Rheum. 1990 Feb;33(2):160-72 [2306288.001]
  • [Cites] Recenti Prog Med. 1990 May;81(5):306-9 [2377807.001]
  • [Cites] Sangre (Barc). 1991 Oct;36(5):377-82 [1816635.001]
  • [Cites] Autoimmunity. 1992;13(2):101-5 [1467431.001]
  • [Cites] Ann Intern Med. 1993 Jun 15;118(12):929-36 [8489106.001]
  • [Cites] Br J Surg. 1993 Sep;80(9):1097-100 [8402103.001]
  • [Cites] FASEB J. 1993 Oct;7(13):1265-8 [8405812.001]
  • [Cites] J Natl Cancer Inst. 1994 Sep 21;86(18):1424 [8072038.001]
  • [Cites] Keio J Med. 1994 Jun;43(2):79-87 [8089958.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):116 [7799490.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;210:337-53 [8565576.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;210:357-9 [8565577.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;210:361-6 [8565578.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;210:367-74 [8565579.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;210:375-83 [8565580.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;210:397-407 [8565584.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;210:411-7 [8565585.001]
  • [Cites] Leukemia. 1996 Feb;10(2):327-32 [8637242.001]
  • [Cites] Regul Toxicol Pharmacol. 1996 Feb;23(1 Pt 1):74-85 [8628923.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4762-9 [8639847.001]
  • [Cites] Ann Plast Surg. 1995 Dec;35(6):561-70 [8748335.001]
  • [Cites] N Engl J Med. 1997 Mar 6;336(10):677-82 [9041097.001]
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1725 [9324032.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3682-90 [9345053.001]
  • [Cites] Pathobiology. 1998;66(6):302-5 [9769477.001]
  • [Cites] J Rheumatol. 1999 Jan;26(1):73-7 [9918243.001]
  • [Cites] Pathol Biol (Paris). 1999 Feb;47(2):119-27 [10192879.001]
  • [Cites] J Rheumatol. 1999 Apr;26(4):816-25 [10229402.001]
  • [Cites] Am J Med. 1999 Jan;106(1):11-9 [10320112.001]
  • [Cites] J Biomed Mater Res. 1999 Jul;46(1):132-4 [10357144.001]
  • [Cites] Biomaterials. 1999 Jun;20(11):1063-9 [10378807.001]
  • [Cites] Postgrad Med. 1999 Aug;106(2):135-42; quiz 185 [10456045.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3646-50 [15529361.001]
  • [Cites] Clin Lymphoma Myeloma. 2005 Sep;6(2):102-14 [16231848.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Clin Diagn Lab Immunol. 2000 May;7(3):366-70 [10799447.001]
  • (PMID = 17875216.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Paraproteins; 0 / Silicone Gels
  • [Other-IDs] NLM/ PMC2212583
  •  go-up   go-down


65. Mencher SK, Wang LG: Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol; 2005;5:3
MedlinePlus Health Information. consumer health - Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An example is chronic myeloid leukemia (CML).
  • DISCUSSION: There is a burgeoning understanding of the cellular mechanisms that control the etiology and pathogeneses of diseases.
  • SUMMARY: We contend that an ideal drug may be one whose efficacy is based not on the inhibition of a single target, but rather on the rebalancing of the several proteins or events, that contribute to the etiology, pathogeneses, and progression of diseases, i.e., in effect a promiscuous drug.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S152-7 [12463468.001]
  • [Cites] BMJ. 1994 Nov 5;309(6963):1215-7 [7987156.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1293-304 [12516962.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 21;301(4):848-54 [12589790.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):819-30 [12755554.001]
  • [Cites] Pharmacol Ther. 2003 Aug;99(2):133-47 [12888109.001]
  • [Cites] Int J Clin Oncol. 2003 Aug;8(4):200-6 [12955574.001]
  • [Cites] Cell Cycle. 2003 Nov-Dec;2(6):538-44 [14504470.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33 [14508090.001]
  • [Cites] Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii13-6 [14532140.001]
  • [Cites] Science. 2003 Oct 10;302(5643):249-55 [12934013.001]
  • [Cites] Mutat Res. 2003 Oct 29;531(1-2):231-51 [14637258.001]
  • [Cites] J Mol Endocrinol. 2003 Dec;31(3):373-99 [14664701.001]
  • [Cites] Nat Rev Genet. 2004 Feb;5(2):101-13 [14735121.001]
  • [Cites] Prostate. 2004 Mar 1;58(4):335-44 [14968434.001]
  • [Cites] Ned Tijdschr Geneeskd. 2004 Feb 21;148(8):371-6 [15032090.001]
  • [Cites] Nat Rev Drug Discov. 2004 Apr;3(4):353-9 [15060530.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):649-53 [15066932.001]
  • [Cites] Rev Gastroenterol Disord. 2004 Spring;4(2):66-85 [15184826.001]
  • [Cites] Semin Vasc Med. 2003 May;3(2):107-12 [15199473.001]
  • [Cites] Ann Ital Med Int. 1995 Jan-Mar;10(1):7-13 [7727211.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1245-6 [7489399.001]
  • [Cites] Adv Cancer Res. 1996;68:67-108 [8712071.001]
  • [Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]
  • [Cites] J Rheumatol Suppl. 1997 Jul;49:15-9 [9249646.001]
  • [Cites] Adv Immunol. 1999;73:79-152 [10399006.001]
  • [Cites] J Pharm Pharm Sci. 2004 Oct 29;7(3):332-6 [15576013.001]
  • [Cites] FEBS Lett. 2005 Apr 25;579(11):2254-60 [15848154.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):305-11 [10559944.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1960-8 [10874065.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):108-15 [11175802.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):683-93 [11870247.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):781-94 [15211575.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):12-21 [15252926.001]
  • [Cites] JAMA. 2004 Jul 28;292(4):419-22 [15280324.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5355-62 [15289342.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5065-71 [15297408.001]
  • [Cites] Trop Gastroenterol. 2004 Jan-Mar;25(1):9-14 [15303463.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):2901-7 [15322145.001]
  • [Cites] Expert Opin Drug Saf. 2004 Sep;3(5):391-403 [15335295.001]
  • [Cites] Indian J Pediatr. 2004 Aug;71(8):713-8 [15345872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073-6 [810797.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • (PMID = 15854222.001).
  • [ISSN] 1472-6904
  • [Journal-full-title] BMC clinical pharmacology
  • [ISO-abbreviation] BMC Clin Pharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational; 0 / Pharmaceutical Preparations
  • [Number-of-references] 48
  • [Other-IDs] NLM/ PMC1090568
  •  go-up   go-down


66. Matsushita K, Ozaki A, Arima N, Tei C: Human T-lymphotropic virus type I infection and idiopathic thrombocytopnic purpura. Hematology; 2005 Apr;10(2):95-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-lymphotropic virus type I (HTLV-I) is the causative agent in adult T-cell leukemia and HTLV-I associated myelopathy.
  • Some other diseases such as uveitis, chronic thyroiditis, Sjögren syndrome, arthritis, acute myeloid leukemia and myelodysplastic syndrome may be also associated with HTLV-I.
  • In the case of ITP patients with HTLV-I infection, the main etiology may be the increased destruction of platelets by immune system.
  • </